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BACTERIAL ETIOLOGICAL AGENTS RESPONSIBLE FOR 
SEPSIS IN CHILDREN AGED 1-36 MONTHS AND 
SUSCEPTIBILITY PATTERNS OF ISOLATES 
BACKGROUND: 
Sepsis is a common cause of morbidity and mortality in pediatric age 
group.Several studies are available for neonatal sepsis.but studies in post 
neonatal age group is limited.Bacterial resistance is recognised as a major 
medical challenge in most healthcare systems. . There is a need for rational 
antibiotic usage based on prevalence of antibiotic resistance based on local 
sensitivity patterns.This study was conducted in the institute of child health 
and hospital for children,Chennai with the aim of isolating and identifying 
bacterial etiological agents responsible for sepsis in children aged 1-36 
months  and  determining the susceptibility patterns of isolates . 
MATERIALS AND METHODS: 
300 Children admitted in ICH &HC fulfilling the inclusion criteria were 
included in the study. Informed consent obtained from parents.About 2 ml of 
blood collected by sterile technique.Blood was collected in BHI broth for 
initial culture by automated blood culture(bacT/ALERT PF) and subcultures 
were done based on isolates.Antibiotic susceptibility of the isolates were 
determined by Kirby-Baeur disc diffusion method.Primary outcomes of the 
study were bacteriae isolated and their  antibiotic susceptibility pattern.The 
secondary outcome studied was their antibiotic resistance 
(ESBL,MRSA,Metallo betalactamases) 
RESULTS: 
The percentage of culture positivity was 27%(80/300).Staphlococcus aureus 
was the most common organism isolated accounting for 58.75% of overall 
isolates.The next most common being klebsiella.(15%)The percentage of 
MRSA of the Staph isolates was 39.1%.The percentage of VRSA was 
17.3%.Among klebsiella ESBL production was 16.67% and all were 
sensitive to meropenam.Enterococci showed high degree of resistance to 
cephalosporins(61.6%).VRE(Vancomycin resistant enterococci) acoounted 
for 16.67%.  Among all isolates ,the antibiotic with maximum coverage was 
amikacin followed by ciprofloxacin.Th overall duration of stay was 11.65 
days.The mortality rate among culture positive patients and culture negative 
patients were 8.75% and 2.7% respectively.Serum procalcitonin levels were 
found to be significantly raised (P<0.01) in culture positive patients when 
compared to culture negative cases. 
 
INTERPRETATION AND CONCLUSIONS: 
There is an shift of organisms grown from the gram negative to gram 
positive spectrum,with the most common organism being Staphlycoccus 
aureus. None of the isolates were H.Influenza meaning increasing 
immunization coverage(74%) against them decreasing their incidence. 
The prevalence of MRSA is high(39%).There is also increasing resistance to 
b-lactam antibiotics among all gram positive isolates and ESBL production 
among kelbsiella.This increases the hospital stay and more monetary 
wastage for the higher antibiotics used and higher toxicity.  
Key words: Bacteremia; Extended-spectrum beta lactamases (ESBLs); 
Klebsiella; Methicillin resistant Staphylococcus aureus (MRSA); 
Staphylococcus aureus 
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INTRODUCTION: 
Sepsis is defined as host response to infection and is an important cause of 
morbidity and mortality all over the world. The Surviving Sepsis Campaign 
pointed out sepsis as a fundamental challenge(1).  
The increasing incidence of sepsis may be linked to chronic diseases, indwelling 
catheters, misuse of antimicrobials and mechanical devices(2). 
Antibiotic therapy in infants and children presents many challenges.There are 
differences among age groups with respect to pathogenic groups responsible for 
infections in the particular age group and also local prevalence and susceptibility 
patterns. 
The wide complexity of organisms necessitates knowledge of local 
susceptibility. 
This study is an attempt to find the bacteria involved in sepsis and their 
antibiotic susceptibility in ICH & HC,Chennai  
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Sepsis is defined as SIRS resulting from a suspected or proven infectious 
etiology. (3)The clinical spectrum of sepsis begins when a systemic (e.g., 
bacteremia, rickettsial disease, fungemia, viremia) or localized (e.g., 
meningitis, pneumonia, pyelonephritis) infection progresses from sepsis to 
severe sepsis (the presence of sepsis combined with organ dysfunction). 
Further deterioration leads to septic shock (severe sepsis plus the persistence 
of hypoperfusion or hypotension despite adequate fluid resuscitation or a 
requirement for vasoactive agents)(3), MODS, and possibly death . This is a 
complex spectrum of clinical problems that is a leading cause of mortality in 
children worldwide. Outcomes improve with early recognition and treatment.
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PATHOPHISIOLOGY OF SEPSIS 
The word sepsis is derived from the Greek word ‗septikos‘, meaning ‗rotten‘ 
or ―to make putrid‖. Sepsis is defined as systemic host response to microbes 
in previously sterile tissue. In its severe form, it is characterized by multitude 
of end-organ dysfunction often away from the prime site of infection. The 
pathophysiology of sepsis is a continuum. The normal response to infection 
is both to identify pathogen invasion and to initiate tissue repair. The immune 
response comprises responses by innate immunity and adaptive immunity. 
The innate immunity response forms front-line reaction against invading 
pathogens. It consists of recognition of components of microbes, activation 
of phagocytosis (e.g. neutrophils, monocytes, eosinophils, and macrophages), 
coagulation, complement system and production of acute phase 
proteins.Adaptive immunity consists of responses by cell-mediated and 
humoral immunity. 
These phenomena function in parallel and are contingent on each other. Both 
these give rise to proinflammatory  and  anti-inflammatory responses. If this 
process is disturbed, a sequence of events take place in which promotion and 
liberation of inflammatory mediators inevitably leads to sepsis.(4) 
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Innate immune response 
The physical barriers to host invasion are externally formed by skin 
and internally formed by mucous membranes lining the gastrointestinal, 
respiratory and  genitourinary tracts. They form a mechanical barrier against 
invading pathogens in assosiation with the normal local flora. In hospital 
environment patient‘s intravenous cannulas, indwelling catheters and urinary 
catheters are considered as possible sources of infection(5).Sepsis may be 
due to numerous invasive pathogens including bacteria, viruses, fungi and 
parasites. The structural components of a microbe responsible for initiating 
the septic process are important for understanding the mechanisms of 
inflammation and also for identifying potential therapeutic targets. Endotoxin 
is a lipopolysaccharide located in the outer portion of cell membrane of 
gram-negative bacteria. Exposure to exotoxins produced by gram positive 
bacteria ,endotoxins or any other types of microbial components initiates 
intracellular events in epithelium ,endothelium, immune cells and 
neuroendocrine system through microbe associated molecular patterns(6) 
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((  
The initiation of response involves pattern recognition receptors which 
recognize specific microbial structures(7). Parts of this are toll-like receptors 
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(TLRs)- transmembrane proteins on the immune cell surfaces. They are 
capable of identifying the invading microbes. Microbes have unique cell wall 
molecules called pathogen-associated molecular patterns (PAMPs). The 
PAMPs adhere to TLRs on surface of immune cells. The binding in turn 
initiates intracellular signaling pathways. As a result of this proinflammatory 
cytokines are released. Monocytes and macrophages also participate in 
secretion of proinflammatory cytokines. Endothelial cells and neutrophils are 
activated to produce adhesion molecules. These help to kill pathogens, but 
also damage the endothelium. Macrophages release VEGF-like molecules, 
which increase vessel permeability and proliferation, leading to coagulation 
and inflammatory processes.(8) 
Adaptive immune response 
Following the initial host-microbe interaction there is activation of  adaptive 
immune response. This coordinates defense responses combining both 
cellular and humoral immune systems. Humoral immune response is 
mediated by antibodies (immunoglobulins) produced in B lymphocyte 
lineage cells (plasma cells). These secreted antibodies bind to antigens 
present on the surface of invading microbes, targeting them for destruction 
by components of the innate immune system. 
16 
 
 
Microbes are destroyed by the phagocytic cells (e.g., macrophages, 
neutrophils, or natural killer cells)along with the help of complement system 
activation or recognition by antibodies.(9) 
Cell mediated immunity is immune response mediated by T lymphocytes. It 
comprises activation of natural killer cells, macrophages, antigen-specific 
cytotoxic T lymphocytes and release of cytokines in response to an antigen.  
17 
 
 
 
Cytotoxic T-lymphocytes (CD8 destroy cells infected by viruses or cells 
containing intracellular bacteriae. Helper T cells (CD4) release cytokines by 
differentiating into type 1 helper T-cells (Th1) and type 2 T helper -cells 
(Th2) (or other subsets of T cells). Th1 secretes pro-inflammatory cytokines 
and Th2  secretes anti-inflammatory cytokines. Proinflammatory cytokines 
(e.g. interleukin-6 (IL-6) ,interleukin-1 (IL-1),  and tumor necrosis factor-
alpha (TNF-α) contribute to elimination of the invading pathogens and anti 
inflammatory mediators (e.g. interleukin-10 (IL-10) and interleukin-4 (IL-4)) 
to control this response.(10) The proinflammatory response leads ultimately 
to damage of host tissues, while the anti-inflammatory response leads to 
leukocyte reprogramming and changes the immune status. During this 
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sequence, circulatory abnormalities (e.g., peripheral vasodilatation, 
intravascular volume depletion and myocardial depression) lead to an 
imbalance between systemic oxygen demand and delivery.(11) 
Complement system, coagulation and inflammation 
The coagulation and complement system are major components of plasma 
cascades. These are closely related and activated in a contiguous manner by 
multiple common stimuli (e.g. infection, trauma).Both these contribute to 
inflammation and mutually interact at various stages.(12) Complement is a 
part of the innate immune system and also a mediator of antibody mediated 
immunity. Its major functions are  defense against pyogenic bacterial 
infections ,linking innate and adaptive immunity and also clearance of 
immune complexes and other products of inflammatory response. Circulating 
components of complement system are activated by three pathways: 
1.The classical pathway :Initiated by  binding of component C1q to antigen 
antibody complex 
2.The lectin pathway:Initiated by binding of mannose-binding 
lectin to the sugars present in bacterial cell wall  
3.The alternative pathway: initiated after exposure to the surface molecules 
of invading pathogens.  
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After the end of these pathways various convertases (e.g. C3, C5) are 
released and these in turn facilitate phagocytosis of opsonised pathogens by 
neutrophils and macrophages, act as mediators of inflammation and 
participate in lysis of bacterial cell membrane. The regulatory mechanisms of 
complement system are balanced sensitively. The ultimate aim is to focus the 
activation of complement onto the surface of invading pathogens and at the 
same time limiting deposition on normal cells.(13) A very delicate balance of 
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pro-coagulant and anticoagulant factors maintains haemostasis.During 
normal conditions three anticoagulant pathways prevent widespread 
activation of coagulation: 
 
1.antithrombin, 
2. activated protein C  
3. tissue factor pathway inhibitor. 
 
During inflammation mediated activation of coagulation, all the three 
functions are impaired; IL-6 release initiates tissue factor upregulation, 
leading to coagulation cascade, whereas TNF-α mediates suppression of 
natural anticoagulants. This leads to Disseminated Intravascular 
Coagulation(DIC), which is thought to be pivotal in the pathogenesis of 
multiorgan dysfunction (MODS) in sepsis. Hence, sepsis is a chaotic 
environment with decreased anticoagulation, exacerbated coagulation and 
impaired fibrin removal.(14) 
Coagulation and complement cascades are intended to act locally. In case 
they are activated systemically due to failure of relevant control mechanisms, 
the effect of this broad activation can be irrevocable. 
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Endothelium and inflammation 
Vascular endothelial cells have an active role in regulation of blood vessel 
permeability, tone, coagulation, angiogenesis and leukocyte and platelet 
activation. Endothelial cells manufacture several pro- and anti-inflammatory 
molecules. They synthesize proteins which increase vascular permeability to 
large molecules (e.g. antibodies and complement components) and to fluid. 
(15) Various microbes adhere to the endothelium, leading to localized 
inflammation and recruitment of monocytes and neutrophils. Increase in 
vascular permeability leads to leukocyte migration into surrounding tissue in 
response to chemotactic factors created at the site of injury. Endotoxins or 
other foreign particles lead to neutrophil activation and also release of pro-
inflammatory cytokines. This adhesion initiates the coagulation cascade. 
Vascular endothelium is one of the main organs involved in pathogenesis of 
sepsis. Damage to endothelium may result in global tissue hypoxia or 
shock.(16) Increasing tissue hypoxia may finally lead to MODS and death.  
MARKERS FOR SEVERE SEPSIS 
In severe sepsis and other high grade infections, circulating levels of 
biomarkers depend on origin and extent of the infection.Also, microbes 
induce a distinct response in several organs, leading to variable diversity of 
biomarkers and mediators. It is obviously evident that any infection is too 
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complex to be confined to  single cutoff of any biomarker. The dynamics of 
biomarker levels have prognostic significance and their  increasing levels are 
found to be associated with  unfavorable outcome and decreasing levels 
suggest favorable outcome.(17) Biomarkers are valuable and helpful tools in 
case of diagnostic dilemma of severe sepsis, especially in delineating severe 
sepsis from less severe forms of sepsis in very early phase of disease. Several 
treatment strategies are effective in sepsis, but the disease must be diagnosed 
early to be treated effectively. 
Early diagnosis with unknown microbiological etiology, but early sepsis 
therapy is more effective than specific sepsis therapy initiated late. (18)This 
is true in neutropenic sepsis, where clinical findings and symptoms of 
infection may be obscure or absent. An ideal prognostic marker should 
distinguish septic infections from various other causes of systemic 
inflammatory response syndrome. The marker should also reflect the severity 
of infection and distinguish time periods with high risk of complications 
from periods with low risk. 
Total leukocyte count and leukocyte differentiation are amongst the oldest 
markers of infection, but they are useless in patients with severe neutropenia. 
Procalcitonin(PCT) ,CRP and proinflammatory cytokines (IL-6 ,IL-8) are 
useful markers of inflammation. In addition to these markers, natriuretic 
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peptides, VEGF, lactate have been persistent interest of study. Various other 
potential future candidates are neopterin, lactoferrin and prostaglandins.(19) 
C-reactive protein 
CRP is a member of acute-phase reactants, because its levels rapidly rise in 
response to any inflammatory process. CRP is produced by hepatocytes, 
mainly under transcriptional control by IL-6. Around 90% of healthy 
population has CRP concentration < 3 mg/l. Synthesis after the initiating 
stimulus beginsrapidly and serum concentrations of CRP rise above 5 mg/l in 
about 6 hours.Peak values are achieved in about48 hours. The only 
determinant of circulating CRP concentration is its synthesis rate and it 
reflects the intensity of pathological process stimulating CRP production. 
(20) As soon as the stimulus terminates, circulating CRP falls rapidly. 
 
Production of CRP is part of nonspecific acute-phase response to various 
forms of  infection, inflammation and tissue damage. Persistent increase in 
CRP also occurs in chronic inflammatory disorders,which includes 
autoimmune diseases and malignancy. CRP has an important role in host 
defense by opsonization, complement action and inducing phagocytosis.(21) 
CRP is used clinically for monitoring autoimmune disorders and infections. 
CRP concentrations are clinically very useful when combined with a full 
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knowledge of all clinical and pathological results. Especially, in severe liver 
diseases CRP is formed at a markedly lower pace than in patients without 
liver disorders.(22)  
The use of CRP is very common in several European countries mainly 
because of easy availability and its low costs in everyday clinical practice. In 
several studies, CRP has been used for comparison of other markers of 
inflammation, chiefly because of its well-known kinetics and its broad use in 
several infectious disease. The time taken from suspicion to diagnosis in 
sepsis is critical because in uncontrolled infections severe sepsis may occur 
rapidly, with a mortality of 20-52%. In recent sepsis studies, the slow 
kinetics of CRP initially has diminished its value as a very early marker of 
sepsis. The diagnostic use of CRP and various other inflammation markers 
was studied in patients with malignancy with suspected infection. Only 
procalcitonin was shown to be a good marker to differentiate bacteraemic 
patients and other patients. 
CRP identifies a patient with infection, but whenever the time interval is 
short (<12 hours), the predictive capacity of CRP declines significantly. 
When kinetics of CRP during infections in leukemia patients were studied, it 
was evident that CRP over 100 mg/l predicted infection.(23) Another study 
evaluated the capacity of CRP and various other inflammatory markers to 
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predict bacteraemia in first 48 hours of fever in patients with 
neutropenia.(24) In initial 10 hours, CRP had a sensitivity of 42% and a 
specificity of 76% for bacteremia. Its positive predictive value was 33%. 
CRP reached its highest levels after 20 to 30 hours in febrile neutropenia in 
patients with bacteremia. 
In another study there were no differences in early CRP concentrations 
between bacteraemic and non-bacteraemic patients.(25) The result was 
similar in the study of Sandri and colleagues(26), where PCT concentrations 
increased early only in bacteraemic patients with the highest levels at day 1 
after the onset of fever. CRP reached its peak level also at day 1 after the 
onset of fever but could not distinguish bacteraemic patients from non-
bacteraemic patients. Based on these studies, CRP is useless from a 
predictive point of view. 
 
Vascular endothelial growth factor(VEGF) 
Vascular endothelial growth factors (VEGF)is an important signaling protein 
involved in both angiogenesis (growth of blood vessels from already existing 
vasculature) and vasculogenesis (de novo formation of embryonic circulatory 
system). 
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VEGF is the most potent factor regulating microvascular permeability and 
angiogenesis. (27)VEGF production is increased in hypoxemic cells. 
Whenever a cell is deficient in O2, it synthesizes hypoxia-inducible factor 
(HIF). This in turn stimulates release of VEGF. The pivotal role of VEGF as 
a mediator of vascular permeability is important in various infections. VEGF 
is found to cause vasodilatation conditioned by endothelial nitric oxide 
synthase (eNOS) in patients with sepsis. (28)Two study groups have reported 
increase of VEGF levels in severe sepsis. Pickkers et al (29) have studied 
septic shock in meningococcal infections as the prototype of gram negative 
septic shock in children. Plasma concentrations of VEGF were measured in 
the first 48 hours and found to be highest in presence of septic shock. 
Concentrations of VEGF at admission correlated with the infection severity 
Van der Flier et al measured VEGF levels in patients having severe sepsis in 
ICU.(30) They have found that VEGF levels were elevated significantly in 
patients with severe sepsis when compared to healthy controls. Also, plasma 
VEGF levels in non-survivors were higher compared to survivors. Increased 
VEGF levels at the entry of study also correlated with the MODS severity 
during the course of the disease. Karlsson et al studied plasmaVEGF levels in 
ICU patients with severe sepsis to predict mortality and organ dysfunction. 
(31)They have found that VEGF levels were raised in patients with severe 
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sepsis when compared with controls. Low levels of circulating VEGF were 
found to be associated with renal and hematological dysfunction, suggesting 
probable disturbed VEGF production in severe sepsis. Further, very low 
VEGF concentrations were associated with mortality and very severe forms 
of organ dysfunction, possibly because of injury to endothelium. 
Amino-terminal pro-brain natriuretic peptide 
Brain natriuretic peptide (BNP) is a pro –hormone which is secreted by 
cardiomyocytes.BNP secretion is primarily a response to increased 
myocardial wall stress and it is aimed to sustain cardiovascular homeostasis 
by its natriuretic, vasodilatory and diuretic properties. (32)NT-pro BNP is an 
inactive metabolite of BNP. NT-proBNP has significantly longer plasma 
half-life and also better stability than BNP.This makes NT-pro BNP better 
applicable for clinical use. Increased in levels of both BNP and NT-pro BNP 
are recognized as early markers of  both increased myocardial dysfunction 
and mortality in ICU setting.(33) Raised levels of natriuretic peptides are 
found to be markers of poor prognosis in patients with severe sepsis and 
septic shock.(34) Also patients with less severe infections seem to have 
raised levels of natriuretic peptides. A positive correlation between increased 
levels of BNP and IL-6 in patient having septic shock has been shown 
previously and in latest studies both BNP and NT-pro-BNP production are 
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linked to general inflammation. Rudiger et al have shown a correlation 
between NT-pro-BNP and also CRP levels in a group of haemodynamically 
unstable patients.Levels of  NT-pro-BNP or BNP did not significantly differ 
between patients with septic shock and those with acute cardiac failure. 
(35)This result was similar to a study by Shor et al, where BNP levels 
positively correlated with CRP in septic patients without myocardial 
dysfunction.(36) Nevertheless, there was found to be  a significant 
association between markedly elevated BNP values and both sepsis and 30-
day mortality in patients . Nikolaou et al have shown that BNP levels were 
raised in acute phase of community-acquired infections without septic shock 
or severe sepsis. (37) 
 
Other markers 
Lactate 
Lactate is a result of balance between lactate production and 
utilization. Hyperlactataemia is present typically in patients with septic shock 
or severe sepsis. In the above said patients both high lactate and poor lactate 
clearance have been recognized as early markers of mortality.(38) 
Hyperlactatemia can be secondary to anaerobic metabolism because of tissue 
hypoperfusion. The prognostic use of elevated serum lactate levels is well 
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established in patients presenting with septic shock, especially if  high levels 
persist. Serial plasma lactate measurements are considered to be better 
indicators of  organ failure and mortality than  single lactate 
determination.(39) 
Evaluation of lactate levels is mandatory to identify tissue hypoperfusion in 
children who are not yet hypotensive, but are at a  high risk for septic shock. 
Estimation of lactate levels in patients is not always straightforward. 
For eg., elevated lactate levels may be due to decreased clearance by liver or 
lactic acidosis rather than global hypoperfusion. In the study by Ramzi et al, 
raised lactate (>3 mmol/l) and low bicarbonate (<17 mmol/l) at the onset of 
bacteraemia were found to be useful biomarkers in predicting mortality and 
septic shock in patients with neutropenia.(40) In a multivariate analysis, two 
variables-pulmonary infection and plasma lactate >3mmol/l were strongly 
associated with septic shock. 
Procalcitonin 
Calcitonin and its precursor procalcitonin (PCT) were used initially as serum 
markers for detection and follow-up of treatment for neuroendocrine 
tumours. Later, PCT levels were found to be elevated in patients with very 
severe systemic inflammation (e.g. systemic bacterial infection, trauma, and 
sepsis). Serum levels of procalcitonin are not detectable in healthy 
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individuals. (41)The production and biological function of procalcitonin 
involves complex and time-dependent mechanisms. Significant production of 
procalcitonin is observed in adherent monocytes, but not found in circulating 
leukocytes.Monocytes produce procalcitonin only for a limited time. 
Parenchymal cells produce procalcitonin after interaction with adherent 
monocytes. Systemic or local inflammations affecting parenchyma and 
monocyte adhesion are preconditions for procalcitonin production. This 
explains why PCT is induced by both local or systemic inflammation and 
tissue trauma. (42) Procalcitonin elevates rapidly (within 2-4 hours) in 
bacterial infections and severe forms of systemic inflammation. It has been 
shown in many settings that serum procalcitonin concentrations increase 
more rapidly than serum CRP concentrations in sepsis patients. In a recent 
review by Sakr et al,PCT was shown to differentiate fever due to systemic  
infection from fever of noninfectious causes.(43) PCT had only a minimal 
role in differentiating gram- positive from gram negative infections.  
In a large meta-analysis, results were similar to the findings of Sakr et al. 
Though high procalcitonin occurred commonly in infection, it was also 
raised in many non-infectious conditions.(44) 
Observations also showed febrile septic patients with documented 
bacteraemia having PCT values within normal range. Therefore, PCT is not a 
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specific indicator of either sepsis or infection and publications regarding its 
prognostic utility are contradictory. (45) 
Interleukins 
Interleukins  (IL-6 &IL-8) are proinflammatory cytokines, mainly 
secreted by monocytes. They are an important part of the cytokine cascade, 
alongwith inhibitory cytokines. The kinetics of interleukins are very fast 
(releasing in less than 1-2 hours) but their concentrations may decline in a 
short period.IL-6 is a multifunctional cytokine which regulates T- and B-cell 
function and acute phase reaction such as CRP secretion. IL-8 is an 
inflammatory cytokine that chiefly functions as neutrophil activating factor 
and chemo-attractant. Engel et al have shown that both IL-6 and IL-8 have 
positive predictive value in neutropenic patients with bacteraemia.(46) 
Especially IL-8 has predictive capacity in this aspect. Anti-inflammatory 
cytokines, mainly interleukin 10(IL-10) and 4(IL-4), are produced to 
downregulate systemic inflammatory response (SIRS) in response to sepsis. 
The role of anti-inflammatory cytokines in various studies is rather obscure. 
Loisa et al studied anti inflammatory response in development of MODS in 
ICU setting, but overproduction of IL-10 was not seen.(47) In another study 
,simultaneous identification of 17 different cytokines have shown that both 
anti- and pro- inflammatory cytokines were significantly elevated in patients 
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with septic shock rather than in patients with severe sepsis.Therefore, higher 
cytokine concentrations were found to be  associated with severity and 
evolution of organ dysfunction, but anti-inflammatory cytokines have no 
specific role in this setting. 
 
INTERNATIONAL CONSENSUS FOR PEDIATRIC SEPSIS- 
DEFINITIONS 
Infection Proven or suspected infection or a clinical 
syndrome  with high probability of infection 
Systemic inflammatory 
response syndrome 
(SIRS) 
2  of 4 criteria, one  must be abnormal leukocyte 
count or abnormal temperature : 
 
1     Core temperature >38.5 C or <36 C 
(bladder, oral, rectal, or central catheter) 
 
2     Tachycardia:  
 
 Mean heart rate >2 SD above 
normal for age in absence of,chronic 
drugs, external stimuli or painful 
stimuli 
OR 
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 Unexplained persistent elevation 
lasting  0.5-4 hr 
OR 
 
 In <1 year old, persistent 
bradycardia over 0.5 hour (mean 
heart rate <10th centile for age 
without vagal stimuli, β-blocker 
drugs, or congenital heart disease) 
 
 
3     Respiratory rate >2 SD above mean for 
age or acute need for mechanical 
ventilation not related to general 
anesthesia or neuromuscular disease 
 
4     Leukocyte count depressed  or elevated 
for age (not secondary to 
chemotherapy) or >10% immature 
neutrophils 
 
Sepsis SIRS and a suspected or proven infection 
Severe sepsis Sepsis and 1 of the following: 
 
1     Cardiovascular organ dysfunction, 
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defined as:  
 
•     Despite >40 mL/kg of 
intravenous isotonic fluid in 1 
hour: 
 
•     Hypotension <5th percentile for 
age or systolic blood pressure 
<2 SD below normal for age 
OR 
 
•     Need for vasoactive agent to 
maintain blood pressure 
OR 
 
•     2 of the following:  
 
•     Unexplained metabolic 
acidosis with base 
deficit > 5 mEq/L 
 
•     arterial lactate: >2 times 
upper limit of normal 
 
•     Oliguria: urine output 
<0.5 mL/kg/hr 
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•     Prolonged capillary 
refill time: >5 sec 
 
•     Core to peripheral 
temperature gap >3C 
 
 
 
2     Acute respiratory distress syndrome 
(ARDS) as defined by the presence of a 
Pao2/Fio2 ratio ≤300 mm Hg, bilateral 
infiltrates on chest radiograph with no 
evidence of left heart failure  
 
 OR 
 
 Sepsis plus 2 or more organ 
dysfunctions (renal, respiratory, 
hematologic, neurologic,  or hepatic) 
 
 
Septic shock Sepsis and cardiovascular organ dysfunction as 
defined above 
Multiple organ 
dysfunction syndrome 
(MODS) 
Presence of altered organ function such that 
homeostasis cannot be maintained without 
medical intervention 
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ETIOLOGICAL AGENTS 
Fever of acute onset, with duration of <1 wk and without any localizing signs 
is a common diagnostic problem in children <36 mo of age. The etiology and 
evaluation of fever without localizing signs depends on the age of the child. 
Traditionally, 3 age groups are considered:  
neonates or infants to 1 mo of age,  
infants >1 mo to 3 mo of age, and 
children >3 mo to 3 yr of age. 
In 1993, practice guidelines were published to help the clinician in evaluating 
an otherwise healthy 0 to 36 mo old presenting with fever without source. 
With the invention and widespread use of the conjugate Haemophilus 
influenzae type b (Hib) and Streptococcus pneumoniae vaccines, the 
incidence of infections with these 2 pathogens have decreased markedly. As 
a consequence, changes to the 1993 guidelines have been advocated 
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IMMUNOCOMPETANT PATIENTS 
Neonates (<28 days) Sepsis and meningitis caused by group B 
streptococcus, Listeria monocytogenes 
,Escherichia coli,; enteroviruses ,neonatal 
herpes simplex virus infection,  
Infants 1-3 mo Serious bacterial disease in 10-15%, 
including bacteremia in 5%; urinary tract 
infection 
Infants and children 3-36 mo Occult bacteremia in <0.5% of children 
immunized with both Haemophilus 
influenzae type b and pneumococcal 
conjugate vaccines; urinary tract infections 
Hyperpyrexia (>40?C) Meningitis, bacteremia, pneumonia, 
hemorrhagic shock-encephalopathy 
syndrome, heatstroke 
Fever with petechiae Bacteremia and meningitis caused by 
H. influenzae type b, Neisseria 
meningitidis and Streptococcus pneumonia 
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IMMUNOCOMPROMISED PATIENTS 
Sickle cell disease Sepsis, pneumonia, and meningitis due to S. 
pneumonia and osteomyelitis by Salmonella and 
Staphylococcus aureus 
Asplenia Bacteremia and meningitis caused by 
H. influenzae type b, N. meningitidis and S.    
pneumonia 
Complement or 
properdin deficiency 
Sepsis caused by N. meningitides 
Agammaglobulinemia Bacteremia, sinopulmonary infections 
AIDS H. influenzae type b, S. pneumonia  and 
Salmonella infections 
Congenital heart 
disease 
brain abscess with right-to-left shunting Infective 
endocarditis 
Central venous line Staphylococcus aureus, , Candida coagulase-
negative staphylococci 
Malignancy Bacteremia with gram-negative enteric bacteria, 
coagulase-negative staphylococci and S. aureus,; 
fungemia with Candida ,Aspergillus 
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ISOLATION 
Isolation of the suspected bacteria is mainly based on culture.The best 
approach is to culture the entire volume of blood in a single aerobic bottle 
because anaerobic bacteremia is rare in children 
ANTIMICROBIAL SUSCEPTIBILITY TESTS 
Antimicrobial susceptibility tests are performed generally on all organisms 
with clinical significance except for few that have predictable antibacterial 
susceptibility patterns (eg.,group A streptococci universally remain 
susceptible to penicillin). The most common technique used is agar disc 
diffusion method (Kirby –Bauer method), in which a standardized 
inoculum of organism is inoculated onto the agar plate. Then, antibiotic-
impregnated filter paper discs are placed over the agar surface. After about 
18-24 hr of incubation, the zone of inhibition against bacterial growth around 
each disc is measured and compared to nationally determined standards for 
resistance or susceptibility. 
Another widely used technique for susceptibility is dilution testing. A 
standard concentration of the microorganism is seeded into serially diluted 
concentrations of  the antibiotic, and minimum inhibitory concentration 
(MIC) in ug/mL, which is the lowest concentration of antibiotic needed to 
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inhibit growth of microorganism is determined. Dilution testing also allows 
the determination of minimum bactericidal concentration (MBC), which is 
the lowest concentration of antibiotic needed to kill the microbe. MBC is 
sometimes determined to eliminate the possibility of bacterial tolerance 
(MBC >4 times MIC) 
ANTIBIOTIC USE IN CHILDREN AND ANTIBIOTIC RESISTANCE 
Antibacterial therapy in infants and children presents several challenges. A 
daunting problem is paucity of data in children regarding pharmacokinetics 
and optimal dosages; unfortunately pediatric recommendations are therefore 
extrapolated from done in adults. A second challenge is the need for clinician 
to consider important differences between various age groups regarding the 
pathogenic species which are responsible for bacterial infections in children. 
Age-appropriate dosing of antibiotic and toxicity must be considered, taking 
into account the physiology and developmental status of infants and children. 
Finally, the style of antibiotics usage has several important differences 
compared to usage in adults. 
Specific antibiotic therapy is driven optimally by microbiologic diagnosis, 
predicated based on isolation of pathogenic organism obtained from a sterile 
body site, and aided by antimicrobial susceptibility testing. Given the 
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inherent problems that arise in collecting specimens from children, and given 
higher risk of serious bacterial infection in young infants, most pediatric 
infectious disease management is based on a clinical diagnosis with 
empirical use of antibiotics before or even without final identification of the 
particular micro-organism. 
Early administration of broad-spectrum antibiotics is associated with 
decreased mortality. The antibiotic choice depends on clinical situation and 
predisposing risk factors. Antibiotic resistance patterns in hospital and 
community must be considered in selection of appropriate antimicrobial 
treatment. 
In infants and children, community-acquired infections by Neisseria 
meningitidis can be empirically treated with a 3rd-generation cephalosporin 
(cefotaxime or ceftriaxone) or high-dose penicillin.  
H.influenzae infections can be empirically treated with a 3rd-generation 
cephalosporin (cefotaxime or ceftriaxone).  
Prevalence of resistant Streptococcus pneumoniae very often requires 
addition of vancomycin, depending on specific clinical situation. 
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Suspicion of community- acquired or hospital-acquired, methicillin-resistant 
Staphylococcus aureus mandates coverage with vancomycin, depending on 
local resistance patterns.  
In case an intra-abdominal process is doubted, anaerobic coverage with an 
antibiotic such as metronidazole, clindamycin, or piperacillin-tazobactam 
should be done. 
Nosocomial sepsis can generally be treated with at least a penicillin with an 
extended gram-negative spectrum (e.g., piperacillin-tazobactam) or a 3rd- or 
4th-generation cephalosporin. An aminoglycoside must be added as and 
when clinical situation warrants. 
Vancomycin must be added to the treatment regimen in the following cases: 
if the child has an indwelling medical device 
2.if gram-positive cocci are isolated from culture 
if methicillin-resistant Staph aureus infection is suspected 
as empirical coverage for S. pneumoniae in a meningitis patients. 
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The above are generalized recommendations that must be tailored to 
individual clinical scenario and to local resistance patterns of the hospital or 
community. 
For more than sixty years, antibiotics have been regarded as panacea to treat 
infections, whether their use is appropriate or not, and whether the infection 
was acquired in the community or in the hospital setting. In his Nobel Prize 
speech in 1945, Alexander Fleming, who discovered penicillin, had warned 
that bacteria would become resistant to the remarkable drugs called 
antibiotics. The development of each new antibacterial agent has been 
followed by detection of resistance. The development of resistance is 
considered a normal evolutionary process for microbes, but it is accelerated 
by selective pressure exerted by the widespread use of antibacterial agents. 
Resistant strains propagate and spread where there is non-compliance with 
control measures and infection prevention. 
 
Use of antibacterial agents has become widespread over decades (although 
equal access to antibacterial agents is not being available worldwide), and 
also these are extensively being misused in both humans and animals in ways 
that favour the selection and spread of resistance.As a result, antibacterial 
drugs are less effective or even ineffective, resulting in accelerating global 
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health security emergency which is outpacing available treatment options 
rapidly. 
Until 1970s, many new antibacterial drugs were discovered to which most of 
the common pathogens were fully susceptible initially, but the latest 
completely new classes of antibacterial agents were discovered during 1980s 
 
 
 
Antibiotic resistance has developed as an alarming problem in child-care, 
because incidence of infection by organisms resistant commonly used 
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antimicrobial drugs has dramatically increased. The estimated annual rate of 
antibiotic usage among children in hospitals is 2 to4 times higher than in age-
matched children cared at home and the average duration of treatment is 4 
times longer amongst children in child care. This high frequency of antibiotic 
usage combined with propensity for person-to-person transmission of 
microbes in a crowded environment resulted in an increased prevalence of 
antibiotic-resistance in bacteria of the respiratory and intestinal tracts, 
including S. pneumoniae, Moraxella catarrhalis, H. influenzae,  , Shigella 
species and E. coli O157:H7.   
WHY IS ANTIMICROBIAL RESISTANCE A GLOBAL PROBLEM? 
Antimicrobial resistance (AMR) kills 
Challenges care and control of infectious diseases 
Greatly increases care costs 
Threatens a return to the pre-antibiotic era 
Jeopardizes healthcare gains for individuals and society 
Compromises health security, damages trade and economy 
Lack of coherent approaches to prevention and containment 
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AVOID ANTIBIOTIC ABUSE (AAA) 
Fostering awareness about antimicrobial resistance and rational antibiotic 
practice is a part of the IAP ICMR Call to Action declared this year. As a 
commitment to reduce antibiotic misuse, September 28 will be observed as 
the Rational Antibiotic Day and the week thereafter, has been declared as 
Antibiotic Awareness Week. September 28 has been selected in 
commemoration with Sir Alexander Flemming‘s discovery of penicillin. 
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PREVENTION OF SEPSIS 
There is increased focus on the prevention of nosocomial infections.This is 
well emphasized by the fact that five of the sixteen elements of Joint 
Comission‘s National Patient Safety Goals (2009) relate directly to 
prevention of health 
Care–associated infection (HAI),being  
1.hand hygiene 
2.major permanent loss of function following HAI or unanticipated death 
3.surgical site infections 
4.central line associated bacteremia 
5.infections caused by multi-drug resistant organisms 
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STEPS FOR PREVENTIONS OS SEPSIS 
 
The most important method in any infection control is to practise good hand 
hygiene.Hands must be cleaned during every patient meeting. Waterless 
hand hygiene increase hand hygiene compliance and also save time; these 
hand hygiene agents are preferred for routine hand hygiene .Universal 
precautions includes use of the following-gloves, goggles, gowns, masks,  
and face shields—for preventing transmission of micro organisms which can 
be transmitted via blood and body fluids.. 
Isolation of patients as and when needed decreases the risk of transmission of 
microbes to other patients and health care personnel. 
Aseptic precautions must be followed during all invasive procedures and    
intravenous and central line catheter placements. The barrier during catheter 
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placement decreases risk of microbial transmission almost by half. It is 
necessary to remove unnecessary catheters as soon as possible 
Immunization with conjugate H. influenza type b and S. pneumonia is 
recommended for all children. High-risk patients in addition must receive 
conjugated pneumococcal vaccine,  23-valent pneumococcal vaccine,and 
also quadrivalent meningococcal vaccine( groups A, C, Y, W-135)  at two 
years of age. 
In patients with functional asplenia (e.g., sickle cell anemia) and anatomical 
asplenia penicillin prophylaxis is recommended.  
In house hold contacts of patients with meningococcal disease or invasive 
H.influenza disease prophylaxis is recommended.  
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REVIEW OF LITERATURE: 
 
STUDY1:WHO REPORT ON ANTIMICROBIAL RESISTANCE 2014: 
Antimicrobial resistance (AMR) in a wide range of infections is a growing 
public health threat both to countries and multiple sectors. 
 
Determining the scope of this problem is of utmost importance for 
monitoring and formulating an effective response to AMR. The WHO report 
which is produced in collaboration with the member States and various other 
partners, provides an accurate idea of the magnitude of AMR and also the 
current state of global surveillance . 
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The high proportion of resistance to the 3rd generation cephalosporins for 
K.pneumoniae and E.Coli means that the treatment of severe infections 
caused by these in many clinical settings must rely on carbapenem group of 
antibiotics,considered the last resort to treat severe hospital and community 
acquired infections. 
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Of concern is the fact that Klebsiella pneumoniae resistant to carbapenems 
also has been identified in most countries that provided data with resistance 
up to 54% reported. 
High rates of MRSA mean that treatment for suspected /verified severe Staph 
aureus infections, like common skin and wound infections should rely on 
secondline agents. Second-line agentsfor S. aureus are very expensive; And 
they have severe side-effects needing monitoring during treatment,which 
increases costs even further. 
Reduced susceptibility to penicillin has been detected in Streptococcus 
pneumoniae in all WHO regions, exceeding 50% in some reports. 
The resistance to quinolones among two of the major causes for bacterial 
diarrhea namelyShigella species and nontyphoidal Salmonella (NTS) were 
found to be comparatively lower than in E. coli. 
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Among a wide range of WHO initiatives, in 2001 Global strategy for 
containment of antimicrobial resistance was published, and antimicrobial 
resistance(AMR)was the main focus of World Health Day 2011 when a 6-
point antimicrobial resistance(AMR) policy package was issued 
 
1.Commitment to  comprehensive, financed national plan with  
              civil society engagement and accountability 
2.Strengthening surveillance and laboratory capacity  
3.Ensuring an uninterrupted access to essential medicines of assured  
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             quality  
4.Regulating and promoting rational use of antibiotics including   
              animal husbandry and ensuring proper patient care 
5.Enhancing infection prevention and control 
6.Fostering innovations and also research and development for new 
tools 
 
RESISTANCE DATA ON SPECIFIC PATHOGENS 
ESCHERICHIA COLI – resistance to 3rd-generation cephalosporins and to 
fluoroquinolones E. coli is part of normal flora of intestine in humans and 
animals. Nevertheless it is the most frequent etiological agent of community 
and hospital acquired urinary tract infections :the most frequent cause of 
bloodstream infections at all ages; associated with many intra-abdominal 
infections such as peritonitis, also skin and soft tissue infections due to 
multiple microorganisms; cause of neonatal meningitis :one of leading 
causative microbe of food borne infections worldwide. 
E. coli infections usually originate from the person who is affected (auto-
infection), but then strains with a specific resistance or disease-causing 
properties are also transferred from animals, between individuals or through 
food chain. 
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Resistance in E. coli develops readily either through mutations, often the 
case for fluoroquinolone, or acquisition of mobile genetic elements, which is 
the case for broad spectrum penicillins (e.g. amoxicillin or ampicillin) and 
also resistance to third-generation cephalosporins. 
Resistance to 3
rd
 -generation cephalosporins is conferred mainly by enzymes 
called extended spectrum beta-lactamases (ESBLs); these destroy many beta-
lactam antibiotics. 
ESBLs can be transmitted between bacteria and between bacterial species. 
As the ESBL containing E. coli strains are also resistant to various other 
antibacterial drugs, carbapenems remain the only available option for severe 
infections. A recent threat is emerging carbapenem resistance in E. coli 
caused by metallo-betalactamases,that confers resistance to almost all 
available beta-lactam antibiotics. 
The WHO report focus is on available data on proportions of E. coli that are 
resistant to third-generation cephalosporins, widely used for intravenous 
treatment of severe sepsis in hospitals, and also to fluoroquinolones,that are 
among the widely used oral antibiotics in the community setting. 
The resistance reported to fluoroquinolones seemed generally higher than for 
third-generation cephalosporins. Similar to resistance to the 3
rd
 generation 
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cephalosporins, there also were reports of resistance to fluoroquinolone in E. 
coli exceeding 50% in five WHO regions. 
 
KLEBSIELLA PNEUMONIAE – resistance to carbapenems and third-
generation cephalosporins Similar to E.coli, bacteria of Klebsiella genus are 
frequent gut colonizers in humans and vertebrates. K.pneumoniae infections 
are common particularly in hospitals invulnerable individuals like pre-term 
infants and immmunocompromised patients, diabetes or alcohol-use 
disorders, and receiving advanced medical care. 
The most common infections are respiratory tract and urinary tract infections 
and, in neonates,they cause bloodstream infections. Klebsiella pneumoniae is 
one of the  common causes of Gram-negative septicemia. The mortality rates 
for Klebsiella pneumoniae hospital-acquired pneumonia depends on severity 
of underlying condition, and can go beyond 50% in vulnerable patients, 
though treated with appropriate antibiotics. 
Similar to other bacteria in health-care settings. Klebsiella pneumoniae 
spreads readily between patients, causing nosocomial outbreaks. Frequently, 
this occurs in intensive care units and newborn care facilities.. K. 
pneumoniae  spread among different hospitals and across country borders via 
transfer of colonized or infected patients has also been documented . 
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EVOLUTION OF ANTIBACTERIAL RESISTANCE IN KLEBSIELLA 
PNEUMONIAE 
Like E. coli, K. pneumoniae acquires resistance to various antibacterial drugs 
mainly via horizontal transfer of genetic elements such as plasmids or 
transposons. Unlike E. coli, K. pneumoniae carries resistance gene 
(betalactamase located in chromosome) that naturally renders penicillins with 
extended spectrum, like ampicillin and amoxicillin ineffective. Resistance to 
various other widely used oral antibacterial drugs like fluoroquinolones (e.g. 
ciprofloxacin) and cotrimoxazole has arisen and spread globally. This means 
that there are very few remaining options for oral antibiotics for Klebsiella 
infections in several parts of the world. 
In 1982, the world‘s first ESBL K. pneumoniae was identified during 
hospital outbreak of K. pneumoniae infections in Germany. Since then about 
200 different ESBL variants have been identified, which have spread rapidly 
worldwide. Moreover, various ESBL variants identified initially in K. 
pneumoniae have transferred subsequently to E. coli. ESBL-producing 
strains are resistant to all beta-lactam antibacterial drugs such as 
cephalosporins and so for these strains, carbapenems are the main treatment 
option remaining. 
58 
 
Worldwide, Klebsiella  pneumoniae is the main cause of infections caused by 
carbapenem-resistant bacteria.All of the important genes which confer 
carbapenem resistance (mediated via carbapenemases) are present in K. 
pneumoniae, therefore rendering almost all treatment options available 
ineffective. For patients infected with these carbapenam resistant bacteria 
there are no treatments effective clinically. 
Majority of sources have reported more than 30 percent resistance among 
K._pneumoniae against 3rd-generation cephalosporins, and in some countries 
more than 60%. 
Very alarming rates of carbapenem resistance almost exceeding 50%  have 
been reported  in Klebsiella  pneumoniae in some patients, for which few 
alternative treatment options are available. 
 
STAPHYLOCOCCUS AUREUS –methicillin resistance 
Staph aureus is a gram-positive bacterium which can be a part of normal 
flora of the skin and the nose, but is one of the most important pathogens in 
humans. 
Staph aureus causes a variety of infections, notably soft tissue,  skin, bone 
and bloodstream infections. Staph aureus is also the most common cause of 
wound infections postoperatively. Some S.aureus strains produce toxins 
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which can cause a wide variety of specific symptoms that includes food 
poisoning and toxic shock syndrome. 
EVOLUTION OF ANTIBIOTIC RESISTANCE IN STAPHYLOCOCCUS 
AUREUS 
When penicillin was introduced first, it was an effective treatment for Staph 
aureus infections, but already resistance had developed during 1940s. The 
resistance was mediated mainly by the production of betalactamase enzyme 
which inactivates drugs like penicillin, amoxicillin and ampicillin. 
Consequently,beta-lactamase-stable drugs (e.g. cloxacillin and methicillin) as 
well as beta-lactamase inhibitor(e.g. sulbactam and clavulanic acid)which 
could be combined with antibacterial drugs were developed. 
S.aureus strains resistant penicillinase stable antibacterial drugs have 
acquired a new gene (mecA) which codes for novel penicillin-binding 
protein(PBP); such strains are called methicillin-resistant 
Staphylococcus_aureus (MRSA). 
The very first strains of MRSA emerged during 1960s. MRSA was initially a 
problem in hospital-acquired infections only. However, over the past decade, 
community-acquired MRSA(ca-MRSA) has significantly increased in 
various  countries. Fortunately though, many of the community-acquired 
MRSA have so far retained susceptibility to various non-beta-lactam 
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antibiotics, whereas most of the health-care associated MRSA are difficult to 
treat multidrug resistant strains. For the latter group, treatment of last resort is 
glycopeptides antibiotics like vancomycin (since 1950s) and teicoplanin, that 
can only be given by intravenous route and also requires careful monitoring 
to avoid adverse drug reactions.  
New treatment options for MRSA (but are associated with problematic side 
effects) have been developed recently: linezolid(since 1970s) and 
daptomycin (since1980s) are the recently licensed antibiotic drugs. 
Data on MRSA among S. aureus were got from 85 (44%) of the WHO 
Member States. 
Most of the reported MRSA proportions exceed 20% in all regions of WHO, 
and   even exceeds 80% in some of the reports. 
STREPTOCOCCUS PNEUMONIAE -RESISTANCE (OR NON-
SUSCEPTIBILITY) TO PENICILLIN 
Worldwide, S. pneumoniae (these bacteria are also called pneumococi) is the 
protean cause of community-acquired pneumonia, which is the main killer 
disease of children less than 5 years of age. Other diseases due to S. 
pneumoniae include, self-limiting infections like acute otitis media, but it 
also extends to cases of invasive pneumococcal disease with very high 
mortality rates such as meningitis. Amongst bacterial causes of meningitis, 
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pneumococi is associated with highest case–fatality rate and it is the most 
likely to leave survivors behind with permanent residual symptoms and 
sequele. 
The clinical burden of S. pneumoniae infection is concentrated in the 
youngest and eldest sections of population. According to an estimate, 
pneumococi caused around  826 000 deaths (582 000—926 000) in children 
of age group  1—59 months.In  HIV-negative children S. pneumoniae 
infection accounts to 11% of deaths in this age group . 
Pneumococci are found commonly in asymptomatic nasopharyngeal carriage, 
the prevalence varies by age and region. Asymptomatic carriage state 
is responsible for most of the transmission inside populations, like day-care 
centres. 
EVOLUTION OF ANTIBACTERIAL RESISTANCE IN 
STREPTOCOCCUS PNEUMONIAE 
Beta-lactam drug resistance in clinical isolates of pneumococci occurs via the 
acquisition of mutations in genes coding for penicillin binding proteins 
(PBPs), which are the essential components of bacterial cell wall. The 
successive acquisition of several mutations in different PBPs results in an 
increasing minimum inhibitory concentration (MICs) for penicillin 
and the other beta-lactam antibiotics. 
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NONTYPHOIDAL SALMONELLA –RESISTANCE TO 
QUINOLONES 
Bacteria of  genus Salmonella are one of the major causes of foodborne 
infections throughout the world. Being a zoonotic pathogen, Salmonella is 
found in the intestine of several food-producing animals like poultry and 
pigs. Usually, infection is acquired by consumption of contaminated food or  
water or of animal origin: chiefly undercooked meat, eggs ,poultry and milk. 
Animal or human faeces also contaminate the surface of vegetables and 
fruits, leading to foodborne outbreaks. 
Most of the Salmonella strains cause gastroenteritis, whereas some strains,in 
particular  Salmonella enterica serotypes namely Typhi and Paratyphi, are 
more invasive and therefore cause the typical enteric fever. Enteric fever is 
more serious infection that poses problem regarding treatment because of 
antimicrobial resistance in several parts of the world. 
EVOLUTION OF ANTIMICROBIAL RESISTANCE IN 
NONTYPHOIDAL SALMONELLA 
Antimicroial resistance varies between various serotypes of nontyphoidal 
salmonella, and this is significant in some of them. In the late1990s and early 
2000s, various clones of multidrug resistant Salmonella have emerged, and 
then they have expanded worldwide. For example, in Salmonella enteric 
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typhimurium,the genomic element which carries resistance to five different 
antimicrobials (ampicillin, chloramphenicol,streptomycin, tetracycline and 
sulfonamides) spreads horizontally among the other serotypes and acquires 
additional resistant determinants. 
 
STUDY 2; 
Pediatric antimicrobial susceptibility trend across the United States Of 
(2005-2011)-Tamma et al 
Carbapenems were the most effective antibiotics against gram negative 
organisms but did not have over 90% coverage against 
Pseudomonas.Incidence of MRSA was 50%.The indicence of MRSA was 
lower in western districts.Resistance to clindamycin was seen in 21% of 
S.Aureus.. Enteroccus faecium showed 25% susceptibility to ampicillin and 
45% to vancomycin.Linezolid resistance was seen in 8% of E. faecium. 
Southern hospitals reported higher E. faecium prevalence with susceptibility 
to vancomycin, ampicillin,  and linezolid compared to other 3 regions (P< 
.01).(50) 
 
 
64 
 
STUDY 3: 
Pediatric bloodstream infections , Cambodia, 2007 to 2011(Stoesser et al) 
Of 7682 blood cultures with results , 606 (7.9%) BSI were found in 
588 children.Increase of incidence of blood stream infections from 14/1000 
to 50/1000 was attributed to increasing sampling.Most  of the infections was 
acquired from community(89.1%). Common pathogens were  S. Typhi 
(22.8%), Staph aureus (12.2%), S.pneumoniae (10.0%), Klebsiella (6.4%) 
and E.coli (6.3%). 21.5% of sepsis was due to unconventional gram negative 
organisms. Listeria monocytogenes and Group B streptococci were not 
identified.Antibacterial resistance was increased more so in the 
enterobacteriaceae family. Overall the mortality was high(19.0%), highest in 
newborn (36.9%)  (51) 
STUDY 4 
Staph aureus infections in children in Iranian tertiary pediatric hospital-
by Sabouni et al(2011-2013) 
During the study period ,the percentage of MRSA infections of all S. aureus 
isolated was 79% (77/98). Additionally, 58/74 (78%) were identified to be 
Hospital- Acquired Methicillin Resistant S. aureus (HA-MRSA) and the 
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remaining  20/24 patients (83%), were identified as Community-Acquired 
Methicillin-Resistant S. aureus (CA- MRSA).(52) 
STUDY 5 
Bacteriological profile and antibiogram of isolates of blood culture from 
a children hospital in Kabul-Tariq et al(2010-2012) 
Positive blood culture  rate was 12.2%. Of the total 410 isolates, 212 
(51.71%) gram-negative bacilli and 184 (44.88%) gram-positive cocci were 
isolated. Additionally, 14 (3.41%) Candida spp were isolated. Most species 
of gram-negative bacteria isolated were Enterobacteriaceae and included 66 
K.pneumonia (16.1%), 42 Enterobacter (10.2%), 35 E. coli (8.5%) and 16 
Serratia (3.9%) spp. 21 (5.12%) Pseudomonas species were isolated. Of the 
gram-positive cocci isolated, most were coagulase-negative Staphylococci 
(26.34%)  andStaphylococcus aureus (11.95%) ,Streptococcus species 
(5.12%). Of the ESBL producing organisms 51.9% were multidrug-resistant 
and had resistance to Ampicillin, Gentamicin, , Fluoroquinolones, 3rd gen 
Cephalosporins and Co-trimoxazole. Most were sensitive to Imipenem 
(200/212, 94.3%), Amikacin (172/212, 81.1%) ,Fosfomycin (166/212, 
78.3%).Of the gram-positive cocci, most isolates were resistant to 
Gentamicin, Penicillin, 3rd gen Cephalosporins, quinolones and 
Cotrimoxazole. Most isolates were found to be sensitive to Pristinamycin 
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(161/184, 87.5%) Vancomycin (183/184)  and Fosfomycin (134/184, 72.8%). 
All S.aureus  were resistant to penicillin and 51% of the isolates were 
MRSA.(53) 
STUDY 6 
A study on bacteriological profile ,antibiogram of organisms causing 
bacteremia  in children less than 10 years in referral hospital in 
bangalore, India-Tiwari et al 
Of  the 128 suspected cases, 32 (25%) were culture positive. Male: female 
ratio was 1.28:1.0. Klebsiella (43.75%) was the most common bacteria and 
next was Staphylococcus aureus (18.75%). The prevalence of gram negative 
bacteria was 71.87%. Most gram negative bacteria maximum resistance to 
ampicillin and the gram positive bacteria to penicillin. Three gram negative 
bacteria produced extended-spectrum beta lactamases (ESBLs) and 
1Pseudomonas aeruginosa produced metallo-beta lactamase 
(MBL).Incidence of MRSA among S.Aureus isolates was 33.33%.(54) 
Our study is attempt to find out the bacterial agents for sepsis and their 
sensitivity/resistance patterns for our local prevalence of infections in our 
hospital to rationalize optimum antibiotic usage 
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OBJECTIVES: 
1.To isolate and identify bacterial etiological agents responsible for sepsis in 
children aged 1-36 months  
2.To determine the susceptibility patterns of isolates  
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METHODOLOGY 
STUDY DESIGN: Prospective descriptive study 
STUDY PLACE: Institute of child health, egmore, chennai 
STUDY PERIOD: Mar 2014- Sept 2014 
STUDY POPULATION: All children in age group 1-36 months with 
suspected bacteremia* 
 
CASE DEFINITION 
INCLUSION CRITERIA: All children in age group 1-36 months with 
sepsis (pediatric consensus on sepsis) and suspected bacteremia*(48) 
Any child 1-36 months toxic appearing and temp >= 38 deg celsius  
Any child 1-36 months presenting with septic shock/severe sepsis  
1-3 months temp >=38 deg celsius with exclusion of low risk infants 
3-36 months temp >=39 deg celsius  
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EXCLUSION CRITERIA: 
Chidren appearing non toxic 
Infants 3-36 months with low risk i.e. 
Uncomplicated history 
Normal physical examination 
Normal lab parameters 
WBC  5000-15000 cells/cumm  
Urine WBC less than 10/hpf  
Stool if diarrhoea (no RBC and WBC less than 10/hpf) 
SAMPLE SIZE: 300 
MANOEUVRE: 
Children fulfilling the criteria for inclusion in study enrolled. 
Informed consent obtained from parents. 
About 2 ml of blood collected by sterile technique(skin disinfected 
with alcohol and povidone iodine) 
 
70 
 
SKIN ANTISEPSIS.  
The likelihood of the isolate from blood culture being a true isolate rather 
than a contaminant depends on the degree os skin antisepsis. The 
recommended antiseptics are 70% isopropyl alcohol,and an iodine tincture or 
iodophor.. 
Blood collected in BHI broth for initial culture by automated blood culture 
directly via a syringe and inoculated into the bacT/ALERT culture media 
under strict asepsis. 
PRINCIPLE OF THE TEST  
BacT/Alert: an Automated Colorimetric Microbial Detection System 
The BacT/ALERT Microbial Detection  is based on the principle of 
colorimery in that there is detection of CO2 production by the micro 
organism which gets dissolved in the media as the organism utilizes the 
media.The CO2 produced is detected via a light permeable sensor located at 
bottom of the bottle indicated by a color changr from blue green  to yellow 
The light color causes an increase of  reflectance units  which is monitored 
by the system. The color reflectance is monitores every 10 minutes 
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BacT/ALERTÆ PF (coded yellow) : 
BacT/ALERT PF culture bottles contain 16ml of complex  
media and  also 4ml of a charcoal with average density of 1.0215 g/mL. The 
media onsists of brain heart infusion  solids (0.1% w/v), soybean-casein 
digest (2.0% w/v), sodium polyanethol sulfonate (SPS)  (0.025% w/v), , 
menadione (0.0000625% w/v), L-cysteine (0.025% w/v), pyridoxine HCI 
(0.001% w/v)hemin (0.000625% w/v), and complex carbohydrate and amino 
acid substrates in water. Bottles contain CO2 atmosphere 
in O2 and N2 under vacuum.  
 
      
 
BACT/ALERT PF 
SYSTEM 
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After the culture bottles are loaded into instrument, they are incubated 5-7 
days until declared positive.  
3. All positive bottles are smeared and sub cultured.If they are false positive 
they are reloaded in the instrument until deemed positive. 
4. Negative bottles are checked by smear and subculture before being 
discarded as negative. 
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Interpretation of Positive Cultures 
Parameters that help  in interpreting results are 
1.The identity of the microorganism,  
2.Presense of the same organism in more than one blood culture 
3.Presence of same microbe in an another normally sterile body site 
 
Microorganisms which mostly (>90% of isolates) represent true infection 
include Escherichia coli ,Staphylococcus aureus,  and other 
Enterobacteriaceae, S.pneumoniae, P. aeruginosa, and Candida albicans. 
Isolates which rarely «5% of isolates) represent true infection are Bacillus 
species, Corynebacterium species, and Propionibacterium acnes. 
LIMITATIONS 
Certain strains of Neisseria meningitidis, Neisseria gonorrhoeae, 
Haemophilus influenzae,  and Peptostreptococcus are sensitive to the 
anticoagulant SPS which results in low production of CO2 culture bottles in 
case of insufficient blood inoculation.  
BacT/ALERT positives may de due to high WBC count.In such cases,further 
subcultures and smears are negative 
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Some pnemococcal strains may get autolysed if they are not subculutures 
immediately 
A Gram-stained smear from negative bottle may contain small number of 
non-viable microbes derived from staining reagents, immersion oil, culture 
medium components,  or glass slides. 
Further subcultures on specific media were done based on the organisms 
isolated . 
The antibiotic susceptibility was done based on KIRBY-BAEUR disc 
diffusion method using standard MIC‘s for the specific organism and the 
antibiotic used. 
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RESULTS 
CULTURE POSITIVITY 
 
Overall positive cultures were obtained in 80 cases among the total 300 cases 
selected for the study yielding a culture positivity rate of 27% overall.
 
 
 
 
 
 
 
 
 
27
73
Culture positivity
Growth
No growth
76 
 
CULTURE POSITIVITY –AGE WISE 
 
 
From the above chart it can be seen that the maximum culture positivity is in 
the age group 1-3 months where the culture positivity rate is 36% whereas 
the culture positive rate in age group 1-3 yrs is only 19 % indicating higher 
prevalence of bacteremia in younger age group.The isolation rate among age 
3 months to 1 year is 24%. 
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ORGANISMS ISOLATED 
The most common organism isolated was Staphlococcus aureus.it was 
isolated from 47 cases-accounting for 58.75 % of culture positive cases. 
The next most common organism was Klebsiella pneumonia which was 
isolated from 12 pcases(15% of total culture positivity). 
E.Coli was isolated in 9 children(11.25%),Enterococci in 6 
cases(7.5%),Streptoccous pnuemoniae in 4 cases(5%) and Pseudomonas 
aeruginosa in 2%(2.5%) 
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78 
 
AGE WISE DISTRIBUTION OF ORGANISMS ISOLATED 
 
AGE-WISE ORGANISM PRESENT (IN NUMBERS) 
 
Age-group 
 
PHEUMO 
 
STAPH 
ORGANISM 
 
EC KL ENT PS TOTAL 
        1-3 M0 3 22 6 5 2 0 38 
3 M0 - I Yr  1 14 2 4 3 0 24 
1Yr-3Yrs 0 11 1 3 1 2 18 
Total 4 47 9 12 6 2 80 
 
It can be seen that the most common organism in all age groups is 
Staphylococcus aureus,contributing to 58% among organisms grown in 1-3 
months,58% in age 3 months to 1 yr and 6% in age 1-3 y.rs respectively 
Of the pneumococci grown 75% were grown in age group 1-3 months. 
Two pseudomonas grown were in the age group 1-3 years.Both the children 
were immunocompromised. 
The second most common organism in the age groups 1-2 months,3 mo-1 yr 
and 1-3 yrs are E.Coli,Klebsiella and Klebsiella respectively 
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AGE WISE DISTRIBUTION OF ORGANISMS 
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SEX DISTRIBUTION OF CULTURE POSITIVITY 
AGE AND SEX-WISE GROWTH AND NON-GROWTH 
 
GROWTH NON-GROWTH TOTAL 
 AGE MALE FEMALE MALE FEMALE MALE FEMALE 
 1-3 M 27 11 44 23 71 34 
 3 M - I Yr  19 5 41 34 60 39 
 1Yr-3Yrs 8 10 44 33 52 43 
 TOTAL 54 26 129 90 183 116 
  
Of the 300 children selected,183 were boys and 111 were females.The 
culture positivity rates in boys was 29%(54/183) and among girls was 
22%(26/116).(P>0.05).No significant statistical difference was noted in the 
isolation rates between boys and girls. 
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EFFECT OF BREAST FEEDING ON CULTURE 
POSITIVITY 
Among the culture isolated cases,in the age group 3 mo-1yr and 1-3 
yrs,14.28% and 28.57% were exclusively breast fed upto six months. 
In the age group 1-6 months,Yes/No was considered on the basis of whether 
the infant was being exclusively breast fed or not. 
Where as among the non-growers the % of breast feeding was significantly 
higher-around 85% and 72% in the age group 3 mo -1 yr and 1-3 yrs 
respectively.(P>0.05) 
AGE 
BREAST FEEDING - AGE-WISE GROWTH AND NO 
GROWTH 
TOT
AL 
GROWTH NON-GROWTH 
BREAST FEEDING BREAST FEEDING 
 
Y N Y N 
 
      1M-3M 20(52%) 19 54 13 106 
      3M-1YR 3(14.28%) 21 69 6 99 
      1YR-
3YRS 4(28.57%) 14 71 6 95 
      TOTAL 27(48%) 54 194 25 300 
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IMMUNISATION 
We considered only immunization against bacterial agents known to cause 
sepsis.The two organisms being H.Influenza and Pneumococci. 
None of the children chosen in our study had received Pneumococcal vaccine 
as it is not covered in the national immunization schedule and all our children 
had received their primary immunization in the government set up. 
H.influenza B vaccine was integrated in the immunization schedule as the 
pentavalent vaccine since December 2012.In our study it was found that 
above the age group of 3 months(where the children are likely to have 
completed their immunization schedule against H.Influenza ) 74.74% had 
received all three doses.Obviously,none of the infants below 3 months have 
completed their three doses of H.Infuenza vaccine 
This introduction of H.Infuenza vaccine has a major impact on isolates as 
there are no isolates of H.Influenza among the culture positive cases. 
 
83 
 
 
AGE 
AGE-WISE     IMMUISATION 
 
TOTAL 
IMMUNISATION 
Y N 
1M-3M 0 106 106 
3M-1YR 64 35 99 
1YR-3YRS 81 14 95 
    TOTAL 145 155 300 
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DURATION OF STAY 
AVERAGE DURATION OF STAY 
AGE-GROUP WISE & GROWTH & NON GROWTH 
 GROWTH NON 
GROWTH 
 TOTAL  
  AVERAGE  AVERAGE  AVERAGE 
1M-
3M 
589/38 15.5 713/67 10.6 1302/105 12.4 
3M-
1YR 
357/24 14.8 787/76 10.5 1144/100 11.4 
1YR-
3YR 
271/18 15 779/77 10.1 1050/95 11 
TOTAL 1217/80 15.2 2279/220 10.4 3496/300 11.65 
 
Overall,the average duration of stay was 11.65 days.The average duration of 
stay among culture positive cases was 15.2 days and among culture negative 
cases was 10.4 days.The longest duration of stay among the different age 
groups was in the 1-3 months category. 
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MORTALITY 
 
 
 
 
 
 
The overall mortality was 13 cases among the 300 (4.35%) of which 7 cases 
were among culture positive cases.These were all caused due to 
Staphylococcus aureus. 
The mortality among culture positive cases was 8.75% and among culture 
negative cases was 2.7% (P<0.05) which was statistically significant. 
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DEATH 
AGE-GROUP GROWTH NON GROWTH TOTAL 
1M-3M 6 2 8 
3M-1YR 1 4 5 
1YR-3YR 0 0 0 
 
TOTAL 7 6 13 
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COMPARISON OF PROCALCITONIN VALUES AMONG 
CULTURE POSTIVE AND CULTURE NEGATIVE CASES 
PCT LEVELS(NG/ML) 
GROWTH WISE - PCT 
TOTAL GROWTH NO-GROWTH 
 0.5-10 1 114 115 
10-50 3 86 89 
50-100 15 16 31 
>100 61 4 65 
TOTAL 80 220 300 
 
 
The levels of procalcitonin was highest in the culture positive  cases when 
compared to culture negative cases.76.25% in the growers had PCT levels 
>100 where as in the culture negative cases  PCT levels more than 100 was 
seen in only 7.27% of cases.(P<0.01) The difference of average PCT values 
amont the two groups was statistically significant. 
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ANTIBIOGRAM 
As discussed earlier the most common organism isolated was staphylococcus 
aureus.Most of the isolates of S.Aureus (among isolated 46 growths) were 
sensitive to amikacin followed by teicoplanin and vancomycin. 
Among the first line of antibiotics,amikacin is the antibiotic having 
maximum sensitivity against all isolates(56/80=70% coverage 
The second antibiotic with maximum action against all organism would be 
ciprofloxacin(54/80=67.5%) 
The antibiogram and resistance patterns of each organism are discussed in 
detail 
 
               
 
               
               
 
               
               
 
               
               
 
               
               
 
               
               
 
               
               
                
TABLE - 12 AMP CLOX OXA CEFOT CFZL AK GA CIP OFLO COT VAN PIP MER TEI 
PNEUMO 
R 3 3 3 1 1 4 4 1 2 3 0 0 0 0 
S 1 1 1 3 3 0 0 2 2 1 4 4 4 4 
STAPH 
R 39 32 31 24 18 5 20 10 21 34 8 0 0 7 
S 7 14 15 22 28 41 26 36 25 12 38 0 0 39 
EC 
R 6 5 5 0 0 3 5 0 1 7 7 0 0 0 
S 3 4 4 9 9 6 4 9 8 2 2 9 9 0 
KL 
R 10 10 10 5 5 5 6 10 9 9 10 2 0 0 
S 2 2 2 7 7 7 6 2 3 3 2 10 12 0 
ENT 
R 3 2 2 4 4 4 5 3 3 3 1 2 2 0 
S 3 4 4 2 2 2 1 3 3 3 5 4 4 6 
PS 
R 2 2 2 1 1 2 0 2 2 2 2 2 0 0 
S 0 0 0 1 1 0 2 0 0 0 0 0 2 0 
TOTAL 
R 66 58 57 33 30 23 39 25 38 60 32 2 2 7 
S 13 21 22 46 49 56 40 54 41 19 47 29 29 41 
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STAPHYLOCOCCUS AUREUS 
Among the 80 patients showing culture positivity ,46(57.5% ) were S.Aureus 
 
Among the first line agents ,amikacin had the maximum sensitivity covering 
89%(41/46) of S.Aureus. 
This was followed by ciprofloxacin-78.2%(36/46) 
The percentage of MRSA was 39.1%(18 of 46 ) of the S.Aureus grown 
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Of the MRSA isolated 88.9% were sensitive to vancomycin followed by 
83.3% sensitivity to amikacin 
 
The percentage of overall resistance to vancomycin was 17.3% (8/36)and to 
teicoplanin was 15.2%.(7/46). 
Two of the staphylococci were resistant to all the above mentioned drugs. 
Further antibiotic sensitivity showed them to be sensitive to linezolid. 
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KLEBIELLA PNEUMONIAE 
The second most common organism isolated overall was Klebsiella 
 
Among the isolates maximum sensitivity was by meropenam.All 
isolates(100%) were sensitive to meropenam. I.e,no carbapenamase 
producing klebsiella were isolated. 
83.3% of isolates were sensitive to piperacillin and 58.33% of isolates were 
senstitive to amikacin. 
Flouroquinolone sensitivity was only 16.6%(2 isolates). 
The percentage of ESBL resistance was 16.67% i.e 2 isolates were resistant 
to penicillin and cephalosporin group of antibiotics. 
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ESCHERICHEA COLI 
9(11.25%) of culture positive isolates were E.Coli 
 
All the isolates were sensitive to cephalosporins,ciprofloxacin,piperacillin 
and meropenam. 
None of the isolates were ESBL producers. 
Resistance to amikacin was seen in 33% (3/9) of isolates. 
Ampicillin resistance was seen in 33% of isolates. 
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ENTEROCOCCI 
Enterococci accounted for 7.5% of the total organisms grown i.e 6 out of 80 
oraganisms. 
 
Among penicillin group,50% were sensitive to ampicillin 3,33% sensitive to 
cloxacillin and oxacillin. 
The enterococci shwed high degree of resistance to cephalosporins with 
66.67% being resistant. 
One of the isolate was vancomycin resistant-VRE(16.67%). 
All the isolates were sensitive to teicoplanin. 
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STREPTOCOCCUS PNEUMONIAE 
Of the organisms isolated pneumococci formed  5%(total of four organisms) 
 
All isolates had 33% sensitivity to ampicillin,cloxacillin and oxacillin. 
66% were sensitive to cephalosporins. 
100% were sensitive to piperacillin,meropenam,vancomycin and teicoplanin. 
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PSEUDOMONAS AERUGINOSA 
Two organisms were isolated and both were in immunocompromised 
patients(under chemotherapy) accounting to 2.5% of total growth. 
 
All isolates were100% resistant to ampicillin,cloxacilli and oxacillin. 
All were sensitive to piperacillin ,ciprofloxacin,amikacin and meropenam. 
Among cephalosporins 50% resistance was observed 
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DISCUSSION 
1.CULTURE POSITIVITY RATE: 
In our study the percentage of positive blood cultures was 27 %(80 out of 
300).. 
In the study by Tiwari et al (Bangalore),the percentage of positive blood 
cultures was similar to our study -25%(32/128) which was similar to our 
study,this being an Indian study. 
In similar studies done in Cambodia by Stoessor et al and in Kabul by Tariq 
et al the percentage of culture positivity was only 7.9%  and 12.2% 
respectively. 
The method and culture media used were not discussed in detail. 
Our study was done using  automated blood culture with inactivating agents 
for antibiotics which probably resulted in a higher yield. 
2.ISOLATES 
In our study the most common organism islated was S.Aureus accounting for 
58.75% (46 isolates) followed by 12 Klebsiella(15%),E.coli(11.25%), 
Enterococci(7.5%)Pneumococci(5%) and Pseudomonas(2.5%) 
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In  the various previous studies majority isolated were gram negative 
organisms in contrast to our study.In the sudy by Stoesser et al,Salmonella 
tpyhi was the most common organism isolated(22.8%) followed by 
Stahylococcus aureus.In study by Tiwari et al,the most common organism 
was Klebsiella(43%) followed by S.Aureus (18.75%).The study by Tariq et 
al shows that CONS was the most common isolate(26.34%) followed by 
klebsiella.Thus the most common organism varied among different studies 
with predominant gram negative organisms.The second most common 
organism in two of the above mentioned studies was S.Aureus which was the 
commonest organism isolated in our study. 
3.ANTIBIOGRAM 
In our study the antibiotic covering most isolates was amikacin (89%) 
followed by ciprofloxacin(78%) 
Of the staphylococci 39% were MRSA in our study compared to 79% in the 
study by Sabouri et al,50% in the study by Tamma et al .In the study by 
Tiwari et al at Bangalore the % of  MRSA was similar to in our study 
i.e.33.33% 
Among the gram negative isolates 51.9%  produced ESBL in the study by 
Tamma et al .In our study EBBL production was 16.7%.The low levels of 
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resistance among the gram negative organisms in our study may be due to the 
isolates being community acquired and more from medical wards rather than 
ICU settings where a high degree of resistance would be seen. 
Most of the gram negative organisms were showing increasing resistance to 
b-lactam antibiotics and most of the staphylococci worldwide are resistant to 
penicillin 
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LIMITATIONS 
Though our study included a large number of patients,group stratification 
based on the foci was not done in view of various difficulties.Further they 
represent only the cases referred to tertiary care centre limiting its application 
to all centres.The differences among immunocompromised and 
immunocompetant patients was not comsidered.Also cases were taken only 
from medical wards and surgical cases were not considered.Anaerobic 
organisms were not considered as they contribute little to pediatric sepsis.The 
percentage of cases from ICU settings was less compared to other studies 
which may account for the lower mortality of sepsis in our study. 
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CONCLUSION 
INTERPRETATION AND CONCLUSIONS 
There is an shift of organisms grown from the gram negative to gram positive 
spectrum,with the most common organism being Staphlycoccus 
aureus.(58%) None of the isolates were H.Influenza meaning increasing 
immunization coverage(74%) against them decreasing their incidence. 
The prevalence of MRSA is high(39%).There is also increasing resistance to 
b-lactam antibiotics among all gram positive isolates and ESBL production 
among klebsiella.(16.67%)This increases the hospital stay and more 
monetary wastage for the higher antibiotics used and higher toxicity.  
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SUMMARY 
This study was conducted in the institute of child health and hospital for 
children,Chennai with the aim of isolating and identifying bacterial 
etiological agents responsible for sepsis in children aged 1-36 months  and  
determining the susceptibility patterns of isolates . 
300 Children admitted in ICH &HC fulfilling the inclusion criteria were 
included in the study.  
Informed consent obtained from parents 
Blood was collected in BHI broth for initial culture by automated blood 
culture(bacT/ALERT PF) and subcultures were done based on isolates. 
Antibiotic susceptibility of the isolates were determined.  
The percentage of culture positivity was 27%(80/300). 
Staphlococcus aureus was the most common organism isolated accounting 
for 58.75% of overall isolates.The next most common being klebsiella.(15%) 
Among the first line agents ,amikacin had the maximum sensitivity covering 
89%(41/46) of S.Aureus.This was followed by ciprofloxacin-78.2%(36/46) 
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The percentage of MRSA of the Staph isolates was 39.1%.The percentage of 
VRSA was 17.3%. 
Among klebsiella ESBL production was 16.67% and all were sensitive to 
meropenam. 
Enterococci showed high degree of resistance to 
cephalosporins(61.6%).VRE(Vancomycin resistant enterococci) acoounted 
for 16.67%.  
 Among all isolates ,the antibiotic with maximum coverage was amikacin 
(70%) followed by ciprofloxacin(67.5%).  
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ABBREVIATIONS 
SIRS-Systemic inflammatory response syndrome 
MODS-Multi Organ Dysfunction Syndrome 
TLR-Toll Like Receptors 
PAMP-Pathogen Assosiated Molecular Pattern 
VEGF-Vascular Endothelial Growth Factor 
TNF-a-Tumor Necrosis Factor alpha 
CRP-C-Reactive protein 
PCT-Procalcitonin 
eNOS –epithelial derived Nitric Oxide Synthase 
BNP-Brain natriuretic peptide 
NT-BNP-Amino Terminal BNP 
AMR-Antimicrobial resistance 
WHO-World Health Organisation 
MIC-Minimum Inhibitory Concentration 
108 
 
ESBL-Extended Spectrum B-Lactamase 
MRSA-Methicillin resistant Staphylococcus aureus 
VRSA-Vancomycin resistant Staphylococcus aureus 
NTS-Non typable salmonella 
VRE-Vancomycin resistant Enterococci 
MICROBES AND ANTIBIOTICS IN TABLES 
PNEUMO-pneumococci 
STAPH-Staphylococcus aureus 
EC-Escherichea coli 
KL-Klebsiella pneumonia 
PSEUDO-Pseudomonas aeruginosa 
ENTERO-Enterococci 
AMPI-Ampicillin 
OXA-Oxacillin 
CLOX-Cloxacillin 
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CEFOTX-Cefotaxime 
CFZL-Cefazolin 
AK-Amikacin 
GA-Gentamycin 
CIPRO-Ciprofloxacin 
OFLO-Ofloxacin 
VAN-Vancomycin 
PIP-Piperacillin 
MERO-Meropenam 
TEICO-Teicoplanin 
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CONSENT FORM 
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PATIENT DATE FORM 
Age 
Gender 
Place 
Socioeconomic status 
Duration of fever 
Assosiated symptoms 
Previous hospitalisation and duration 
Prior antibiotics  and duration(past two weeks) 
Immunosuppresion* 
Immunisation(pneumococcal,Hib) 
Peak temperature 
Total counts 
CRP 
PCT 
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CXR 
Focus* 
Grams stain 
Culture isolate 
Antibiotic susceptibility 
Emperical antibiotic 
Breast feeding 
Duration of stay 
Outcome  
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NAME AGE IP NO SEX SOCIOECONOMIC STATUS BREAST FEEDING IMMUNISATION DURATION OF STAY OUTCOME TC CRP PCT NEC ORGANISMAMPI CLOX OXA CEFTX CEFAZ AK GA CIPRO OFLO COT VAN PIP MER TEI
GOWTHAM 1 804045 M 5 N N 10 C 2 P 4 G PNEUMO R R R S S R R S S R S S S
GOPI 2 804755 M 3 Y Y 8 C 1 P 1 NG
SARAVANAN 3 804762 M 4 Y Y 7 C 2 P 2 NG
DEEPIKA 2 806166 F 3 Y N 9 C 2 P 1 NG
DAVID 1 806165 M 5 Y N 21 D 1 P 4 G STAPH R R R R R S R S S R R R
DIVYASUGANTHI 3 806302 F 4 N N 15 C 1 P 3 G STAPH R R S S S S R S R R R S
CHRISTINA 2 806456 F 3 Y Y 7 C 2 P 2 NG
VELMURUGAN 2 806475 M 5 Y N 4 D 1 P 2 NG
SURESH 1 806465 M 3 Y N 10 C 2 P 1 NG
YAASINI 2 806988 F 4 Y N 15 C 2 P 3 G STAPH R R R S R S S S S S S S
ILAVARASI 1 807061 F 5 Y N 15 C 1 P 4 G STAPH R R R S S S S S R R R R
SATHISH 1 807065 M 3 Y N 14 C 2 P 3 G EC S S S S S S S S S S S S
SHOBANA 2 807073 F 4 Y Y 8 C 2 P 1 NG
KAMALAKANNAN 1 807071 M 5 N N 21 C 1 P 4 G STAPH R R R R R S R S R R S S
SHARUN 1 807200 M 4 Y N 10 C 1 P 1 NG
DIWAKAR 2 807183 M 5 N N 15 C 2 P 4 G STAPH R R R S S S R S R R R S
DIVYASREE 3 807916 F 4 Y Y 11 C 2 P 2 NG
HARISH 2 807892 M 3 N Y 8 C 2 P 1 NG
HEMANTH 3 807806 M 4 N N 14 C 1 P 3 G KL R R R S S S S S S R R S S
MADAN 3 807823 M 3 Y Y 10 C 2 P 2 NG
SANJANA 2 808612 F 4 N N 7 C 2 P 2 NG
GOKUL 2 808141 M 3 Y Y 8 C 2 P 1 NG
ADITYA 3 808120 M 5 N N 16 C 2 P 3 G ENT S S S S S S S S S S S S
MONISHA 3 808215 F 3 Y Y 9 C 2 P 2 NG
LAKSHMI 2 806240 F 4 Y Y 13 C 2 P 1 NG
ALAN 1 808603 M 5 Y N 16 D 1 P 4 G EC R R R S S S S S S S S S S
DIVYA 3 809063 F 3 Y Y 8 C 2 P 2 NG
SIVARASHMI 2 808874 F 3 Y Y 10 C 2 P 2 NG
SANJAY 3 809276 M 4 Y Y 8 C 2 P 1 NG
AKASH 2 807333 M 4 Y Y 12 C 2 P 2 NG
PRIYA 1 809459 F 5 N N 16 C 1 P 4 G KL S S S S S S S S S S S S S
PORSELVI 3 809472 F 3 Y N 11 C 2 P 2 NG
PARGAVI 2 809464 F 4 Y Y 16 C 2 P 1 NG
RITHISH 2 809512 M 5 N N 17 C 2 P 4 G STAPH R R R R R R R S S R S S
VETRIVEL 3 805969 M 3 Y Y 8 C 2 P 2 NG
PRINCE 1 809599 M 4 N Y 10 C 2 P 1 NG
DILLIBABU 2 809605 M 4 N N 17 C 1 P 3 G EC R R R S S S S S S R R S S
PRAVEEN 3 810230 M 4 Y Y 8 C 2 P 2 NG
YASHWANTH 1 810256 M 3 N N 9 C 2 P 1 NG
SURYA 2 810371 M 5 Y N 7 C 2 P 1 NG
GOKULRAJ 1 810205 M 5 N N 16 D 1 P 4 G STAPH R R R R R S S S R R R R
SWETHA 3 810200 F 3 Y Y 10 C 2 P 2 NG
DHARSHAN 2 810282 M 4 N N 16 C 2 P 3 G EC R R R S S S S S S R R S S
BHUVANESH 1 810322 M 3 Y N 11 C 2 P 1 NG
DHANUSREE 1 810404 F 4 Y N 14 C 2 P 4 G STAPH R R R R R S R R R R S S
DHANUSH 3 810407 F 4 Y Y 11 C 2 P 2 NG
KEERTHIKA 2 810448 F 3 Y Y 12 C 2 P 1 NG
SIVASANKARI 1 810458 F 3 Y N 13 C 1 P 2 NG
SANTHOSH 2 812335 M 3 Y Y 8 C 2 P 2 NG
MONISH 1 812414 M 4 N N 15 C 1 P 4 G KL R R R R R R R S S R R S S
KEERTHIKA 3 812496 F 3 Y Y 11 C 2 P 2 NG
NIRUPAM 2 812495 M 3 Y N 9 C 2 P 1 NG
JENANI 1 812793 F 3 Y N 8 C 1 P 1 NG
B/O CHITRA 1 813223 F 5 Y N 17 D 1 P 4 G ENT R R R R R R R R R R R R R
B/O SANJANA 1 813254 F 5 Y N 14 C 1 P 3 NG
JEYENDARAN 2 813783 M 3 Y Y 15 C 2 P 1 NG
NAREN 3 813777 M 3 Y Y 8 C 2 P 2 NG
JAGADEESH 3 813912 M 5 N N 17 C 2 P 2 G PS R R R R R R R S R R R S S
KIRTHIK 2 813931 M 4 Y N 11 C 2 P 2 NG
SHEWTHA 3 813997 F 4 N N 12 C 1 P 3 G STAPH S S S S S S S S S S S S
VIGNESH 2 814361 M 5 N N 12 C 2 P 4 G STAPH R S S S S S S S S R S S
APPU 1 814350 M 5 N N 14 C 1 P 4 G STAPH R R R R R S R R R R S S
KARTHIK 3 814582 M 3 Y Y 8 C 2 P 2 NG
SHALINI 2 814662 F 4 Y Y 9 C 2 P 1 NG
SHANMATHY 1 814613 F 3 N N 8 C 2 P 1 NG
LOKESHWARI 3 814649 F 3 Y Y 9 C 2 P 2 NG
TEJESHWARI 3 815305 F 3 Y Y 9 C 2 P 1 NG
VETRIVEL 1 815747 M 5 N N 14 D 1 P 4 NG
DIWAKAR 2 815698 M 4 N N 16 D 2 P 3 NG
JEYACHANDRAN 2 815758 M 4 N N 14 C 2 P 4 G KL R R R S S S S S S R R S S
VIMALESH 1 815764 M 5 Y N 17 C 2 P 3 G STAPH R R R S S S S S R R S R
ASMI 3 816160 F 3 Y Y 11 C 2 P 2 NG
LAKSHMI 2 816162 F 3 Y Y 13 C 2 P 2 NG
GANESH 1 816172 M 3 N N 15 C 2 P 2 NG
VETRI 2 815766 M 4 Y Y 9 C 2 P 1 NG
DIWAKAR 3 815699 M 5 Y Y 10 C 2 P 3 NG
JAGADEESH 1 816400 M 5 N N 16 C 2 P 4 G PNEUMO R R R S S R R S R R S S S
HARSHIKA 2 816399 F 4 Y Y 11 C 2 P 2 NG
YOSHITHA 3 816428 F 4 Y Y 12 C 2 P 1 NG
PREETHI 2 817029 F 5 N N 16 C 2 P 4 G STAPH R R R S S S R S S R S S
OVIYA 1 817004 F 3 Y N 11 C 2 P 3 NG
SRUTHIKA 2 817006 F 3 Y Y 12 C 1 P 2 NG
PREETHIKA 3 817038 F 4 Y Y 13 C 2 P 2 NG
PRIYADHARSHIINI 1 817685 F 5 Y N 17 C 1 P 4 G EC R R R S S S R S R R R S S
LOGESHWARAN 3 817682 M 3 Y Y 8 C 2 P 2 NG
LAKSHITHA 2 817782 F 4 Y N 9 C 2 P 1 NG
SAFI 1 818840 M 3 Y N 7 C 2 P 1 NG
VIGNESHWARAN 3 818903 M 3 Y Y 9 C 2 P 1 NG
VIJAY 3 818897 M 5 N N 18 C 2 P 4 G KL R R R R R R R R R R R S S
JAGADESHWARAN 1 818973 M 5 N N 16 C 2 P 3 G STAPH S S S S S S R S S R S S
THIRUMALAI 3 819012 M 3 Y Y 11 C 2 P 1 NG
LOKESH 2 818977 M 4 Y Y 12 C 2 P 1 NG
PURUSOTHAMAN 1 818983 M 3 N N 12 C 2 P 1 NG
JABIN 1 819444 M 5 Y N 15 C 1 P 4 G STAPH R R R R R R R S R R S S
JAGADEESH 2 819462 M 4 N N 16 C 2 P 4 G ENT R R R S S R R R R R R S S
SANTHOSH 3 819820 M 3 Y Y 9 C 2 P 2 NG
NANDITA 1 819730 F 3 Y N 8 C 2 P 1 NG
LAKSHMI 3 820245 F 3 Y Y 8 C 2 P 2 NG
SHOBIKA 2 820299 F 3 Y N 9 C 2 P 1 NG
VIGNESH 2 820268 M 3 Y N 11 C 2 P 1 NG
PRIYADHARSHINI 2 820322 F 3 Y Y 12 C 2 P 2 NG
LAKSHMI 1 820647 F 4 N N 13 C 2 P 4 G PNEUMO R R R S R R R S S R R S S
GOWTHAM 2 820644 M 5 N Y 15 C 1 P 4 G STAPH R S S S S S R S R R S R
PRADDEPRAI 3 820637 M 3 Y Y 14 C 2 P 2 NG
GOKUL 1 820679 M 4 Y N 8 C 1 P 1 NG
AMLU 2 820717 F 5 N Y 9 C 2 P 1 NG
KAVIYARASU 3 820782 M 3 Y Y 7 C 2 P 2 NG
HARIKRISHNAN 1 820865 M 5 N N 16 C 1 P 4 G
AJAY 2 820853 M 3 Y N 12 C 2 P 2 NG
ASHIKA 3 820857 F 3 Y Y 11 C 2 P 1 NG
JAYASURIYA 2 820935 M 5 N N 16 C 2 P 4 G PNEUMO R R R S S S S S S S R S S
KAMESHWARAN 3 820906 M 3 Y Y 13 C 2 P 2 NG
SANDHYA 1 820996 F 3 Y N 14 C 2 P 1 NG
AARTHI 2 820712 F 4 Y Y 15 C 2 P 2 NG
RASHIKA 3 821062 F 5 N Y 16 C 2 P 4 G STAPH R R R R S S S S S R S S
SAIBALAJI 1 821060 M 3 Y N 11 C 2 P 1 NG
ANJALAI 2 821051 F 4 N Y 15 C 2 P 4 G STAPH R R R R R S S R R R S S
KISHORE 3 821032 M 3 Y N 10 C 2 P 2 NG
THIRUVASAGAM 1 821117 M 5 N Y 15 C 2 P 4 G STAPH R R R R S S S S S S S S
NISHA 2 821142 F 3 Y Y 9 C 2 P 3 NG
LAKSHITHA 3 821198 F 3 Y Y 11 C 2 P 2 NG
KAVIYA 1 821242 F 3 Y N 12 C 1 P 1 NG
ROSHINI 2 821211 F 3 Y Y 10 C 2 P 2 NG
SHEIKDAVID 1 821327 M 4 Y N 15 C 2 P 4 G STAPH R R R S S S S S R R S S
PRAGADEESH 2 821353 M 5 N Y 16 C 1 P 3 G STAPH R R R R R S R R S R R R
SUKUMAR 3 821321 M 3 Y Y 9 C 2 P 1 NG
SRINATH 1 821320 M 3 Y N 8 C 2 P 1 NG
THARUNKUMAR 2 821565 M 3 Y Y 9 C 2 P 1 NG
PRANAV 3 818125 M 3 Y Y 9 C 2 P 2 NG
JERIN 1 821612 M 3 Y N 8 C 1 P 1 NG
SIVAPRAKASH 2 821736 M 3 Y Y 7 C 1 P 1 NG
GOPIKRISHNAN 3 821818 M 3 Y Y 10 C 2 P 1 NG
SURYA 1 821817 M 3 Y N 11 C 2 P 2 NG
MONISHA 2 821923 M 3 Y Y 12 C 2 P 1 NG
LINGESHWARAN 3 821903 M 3 Y Y 9 C 2 P 2 NG
B/O DIVYA 1 821915 F 4 Y N 16 D 1 P 4 G EC S S S S S S R S S R R S S
AYESHA 3 821882 F 3 Y Y 11 C 2 P 2 NG
HARIKRISHNAN 1 820865 M 3 Y N 12 C 1 P 1 NG
UDAYASHANKAR 2 822370 M 3 Y Y 13 C 2 P 1 NG
MD SUJITH 3 822398 M 4 Y Y 9 C 2 P 1 NG
REENA 1 822396 F 5 N N 17 C 2 P 4 G KL R R R R R R R S S R R S S
DHARSHINI 2 822356 F 4 Y Y 7 C 1 P 2 NG
RITHISH 3 822413 M 3 Y Y 8 C 1 P 3 NG
RAJKUMAR 3 822911 M 3 Y N 15 C 1 P 2 NG
KARTHIK 1 823139 M 3 Y N 11 C 2 P 1 NG
SAKTHIVEL 2 823123 M 3 Y Y 12 C 2 P 1 NG
DHANAM 3 823036 F 5 Y Y 16 C 1 P 4 G STAPH R S S R R S S S S S S S
AKBAR ALI 1 823028 M 4 Y N 9 C 1 P 2 NG
MAXON 1 823647 M 3 Y N 8 C 2 P 2 NG
SIVAPRAKASH 2 823642 M 3 Y N 9 C 2 P 1 NG
CHEZHIYAN 3 823440 M 3 Y Y 7 C 2 P 1 NG
KABILESH 3 823929 M 5 N Y 14 C 1 P 4 G STAPH R R R S S S R S S R S S
RISHIBALAN 1 823931 M 5 N N 15 C 1 P 4 G STAPH S S S S S S S S S S S S
ABHILESH 2 823924 M 4 Y Y 16 C 2 P 4 G ENT R R R S R R R S S R S S S
ATHISH 3 823996 M 3 N Y 9 C 1 P 3 NG
DIVYADHARSHINI 1 823992 F 3 Y N 9 C 2 P 2 NG
GIRIRUDHAN 1 823994 M 3 Y N 8 C 1 P 1 NG
DHARMADURAI 1 824213 M 3 Y N 7 C 1 P 1 NG
CHAITANYA 2 824358 M 3 Y Y 9 C 2 P 1 NG
SOLOMON 3 821287 M 3 Y Y 10 C 2 P 1 NG
SAM 3 824376 M 3 Y Y 11 C 2 P 2 NG
MADHAN 3 824326 M 3 Y Y 8 C 2 P 1 NG
EBENEZER 1 825256 M 4 Y N 9 C 1 P 1 NG
BHAVASREE 2 825267 F 3 Y N 9 C 1 P 1 NG
SRINISHA 3 825672 F 3 Y Y 10 C 2 P 1 NG
SANJAI 1 825673 M 3 N N 11 C 1 P 1 NG
DEVA 2 825861 M 3 Y Y 12 C 2 P 2 NG
NAVYASHREE 3 825913 F 5 N Y 16 C 2 P 4 G STAPH R S S S S R R S S R S S
NIRANJAN 3 825702 M 3 Y Y 9 C 2 P 1 NG
VIKASH 1 825558 M 3 Y N 8 C 1 P 2 G STAPH R R R R S R R S R R S S
B/O NEHA 1 825805 M 5 Y N 15 C 1 P 4 NG
THARUN 3 825605 M 3 Y Y 8 C 2 P 2 NG
DHARSHAN 1 826151 M 3 Y N 9 C 1 P 1 NG
BEULAH 2 826578 F 3 Y Y 12 C 2 P 1 NG
B/O NAGAVENI 1 826598 F 5 N N 16 C 2 P 4 G EC S S S S S R R S S R R S S
DHARSHINI 1 827137 F 3 Y N 9 C 1 P 2 NG
RANI 3 827120 F 3 Y Y 8 C 2 P 1 NG
HARIHARAN 1 827063 M 3 Y N 9 C 2 P 1 NG
NISHANTHI 2 825015 M 3 Y Y 10 C 2 P 1 NG
BHUVANESH 3 827129 M 3 Y Y 11 C 2 P 1 NG
MAHIDAS 1 827106 M 3 Y N 12 C 2 P 1 NG
B/O RAJESHWARI 1 828573 F 5 Y N 16 C 1 P 4 G STAPH R R R R R S S R R R S S
B/O VASANTHI 1 828635 M 5 Y N 17 C 1 P 4 G STAPH R R R R R S S R R R S S
SANJAI 2 829161 M 3 Y Y 8 C 2 P 1 NG
DHARNIKA 3 829162 F 3 Y Y 9 C 2 P 1 NG
NANDHU 2 829111 F 3 Y Y 10 C 2 P 2 NG
TAMILISAI 3 829176 F 3 Y Y 9 C 2 P 1 NG
BHOOPATHY 1 828813 M 4 Y N 11 C 2 P 1 NG
SANDHYA 2 829530 F 3 Y Y 12 C 2 P 2 NG
ASHWINI 3 829549 F 3 N Y 13 C 2 P 1 NG
SUDHARSHAN 1 828186 M 4 Y N 10 C 2 P 1 NG
DEEPANRAJ 3 829342 M 5 Y Y 11 C 2 P 4 G EC R S S S S R R S S R R S S
POOVARASAN 1 829245 M 4 Y N 12 C 1 P 1 NG
KAVISRI 2 829242 F 3 N Y 14 C 2 P 4 G KL R R R S S S S S S S R S S
KAMALI 3 829259 F 5 N N 15 C 1 P 2 NG
SANTHOSH 1 824566 M 4 Y N 15 C 2 P 1 G STAPH R R S R S R S S S R S S
VISNU 1 824535 M 3 Y N 16 C 2 P 1 NG
SUDEESH 3 830841 M 3 Y Y 14 C 1 P 2 NG
ROSHAN 2 830842 M 3 Y Y 9 C 1 P 1 NG
SARADISREE 3 830860 F 3 Y Y 11 C 2 P 1 NG
B/O SINDHU 1 831072 M 3 Y N 12 C 2 P 1 NG
VEDAPRIYA 2 831073 F 3 Y Y 13 C 2 P 2 NG
PRITHVI 3 831074 M 4 Y Y 14 C 2 P 1 NG
B/O SHYAMA 1 831112 M 5 Y N 15 C 2 P 3 G STAPH R R R R R S S S S S S S
SAMUVEL 2 831114 M 4 Y Y 9 C 2 P 2 NG
KRITHIKA 3 831120 F 3 Y Y 8 C 2 P 1 NG
LILITHA 2 831123 F 3 Y Y 7 C 2 P 1 NG
RAKSHITHA 1 831124 F 3 Y Y 9 C 2 P 2 NG
GOKILA 3 831601 F 3 Y Y 13 C 2 P 1 NG
DINESHBALA 1 831581 M 4 Y N 14 C 1 P 1 NG
NITHISWARAN 2 824506 M 5 N N 15 D 1 P 4 G STAPH R R R R S S R S S R S R
AASHIKA 2 826405 F 3 N Y 14 C 2 P 2 NG
DEVIPRIYA 3 832226 F 3 Y Y 10 C 2 P 1 NG
RAKESH 1 832197 M 4 Y N 9 C 2 P 2 NG
RAJAN 1 832288 M 5 Y N 17 C 1 P 4 G EC R R R S S R R S S R R S S
B/O SUJATHA 2 832422 M 5 N Y 12 C 1 P 3 G KL S S S S S S R S S R R S S
EPZIBA 3 832705 F 3 Y Y 14 C 2 P 1 NG
DHARSHAN 1 832721 M 3 Y N 11 C 2 P 1 NG
PADMESH 2 832712 M 3 Y Y 16 C 1 P 1 NG
SUJI 1 832596 F 3 N N 11 C 1 P 1 NG
IBRAHIM 3 832707 M 3 Y Y 12 C 2 P 2 NG
HARIPRIYA 2 832474 F 3 Y Y 13 C 1 P 1 NG
HEMANTH 1 832500 M 3 Y N 14 C 2 P 1 NG
JEEVITHA 3 833201 F 5 N N 15 C 2 P 4 G STAPH R R R R S S R S S R S S
SRILAKSHMI 2 833548 F 4 Y N 9 C 1 P 1 NG
PRATHIKA 2 833380 F 5 N N 14 C 2 P 4 G STAPH R R R R S S S R R S R S
FEROZ 3 833970 M 3 N Y 9 C 2 P 2 NG
SUBASHREE 1 833448 F 3 Y N 8 C 2 P 1 NG
MOHITH 2 833449 M 3 Y Y 10 C 1 P 1 NG
MADHU 1 833403 F 3 Y N 11 C 2 P 1 NG
GURUDHARAN 2 833476 M 3 Y Y 12 D 1 P 2 NG
BHARATHI 3 833452 F 3 Y Y 13 C 1 P 1 NG
ABHIBA 1 833114 F 3 N N 15 C 2 P 1 NG
SAIKRISHNAN 2 833677 M 4 N Y 16 C 1 P 4 G STAPH R R R S S S S R R R R S
SUMITHRA 3 833657 F 5 N N 16 C 2 P 4 G KL R R R S R R R S R R R S S
B/OLATHA 1 833688 M 3 N N 9 C 1 P 2 NG
NAVEEN 2 833646 M 4 Y Y 8 C 2 P 1 NG
MAITHESH 3 833654 M 3 Y Y 10 C 2 P 1 NG
B/O NEELAVENI 1 833652 F 3 Y N 9 C 1 P 2 NG
NITHYA 3 833694 F 3 Y Y 9 C 1 P 2 NG
SAIHARISH 1 833629 M 3 N N 9 C 2 P 1 NG
JENINA 2 833665 F 3 Y Y 8 C 2 P 3 NG
YUVASHREE 3 833909 F 3 Y Y 7 C 2 P 1 NG
LOGANATHAN 1 833928 M 3 Y N 10 C 2 P 2 NG
KRISHNAN 2 833937 M 3 Y Y 11 C 2 P 1 NG
ABHISHYA 3 833895 F 3 N Y 12 C 1 P 1 NG
SAMEER 2 833884 M 4 N N 14 C 1 P 4 G STAPH R R R R R S S S R R S S
SUNDARABALAN 1 833929 M 5 N N 15 C 1 P 4 G STAPH R R R R R S R R R R S S
DEEPIKA 1 834227 F 4 Y N 11 C 2 P 3 NG
DHANAM 3 834229 F 5 Y Y 16 C 1 P 4 G STAPH R S S R R S S S S S S S
ALIULLAH 1 834230 M 4 Y N 9 C 1 P 2 NG
AVINASH 1 834234 M 3 Y N 8 C 2 P 2 NG
SIVAPRAKASH 2 834240 M 3 Y N 9 C 2 P 1 NG
CHELLIAH 3 834244 M 3 Y Y 7 C 2 P 1 NG
KAVIN 3 834245 M 5 N Y 14 C 1 P 4 G STAPH R R R S S S R S S R S S
RISHIBALAN 1 834247 M 5 N N 15 C 1 P 4 G STAPH S S S S S S S S S S S S
ABINAV 2 834278 M 4 Y Y 16 C 2 P 4 G ENT R R R S R R R S S R S S S
LOHITH 3 834396 M 3 Y Y 13 C 2 P 2 NG
ASHMITHA 1 834579 F 3 Y N 11 C 1 P 3 NG
B/O KALPANA 2 834564 F 3 Y Y 8 C 2 P 2 NG
JOEL 2 835297 M 5 N N 14 C 1 P 4 G STAPH S S S S S S S S S S S S
SIVABALAN 3 836020 M 4 N Y 10 C 1 P 2 NG
ABDUL RAHIM 1 835994 M 3 Y N 11 C 2 P 2 NG
MUKESH 3 835984 M 3 Y Y 13 C 1 P 1 NG
DHARUN 1 835978 M 5 N N 16 C 1 P 4 G KL R R R R S S S S S S S S S
DIVYADHARSHAN 2 835995 F 3 Y Y 18 C 2 P 3 NG
SRIDAR 2 835982 M 3 Y Y 11 C 1 P 2 NG
SANTHOSH 1 835983 M 3 Y N 12 C 2 P 3 NG
SHANMUGAPRIYA 3 835992 F 3 Y Y 16 C 1 P 4 G STAPH S S S S S S S S S S S S
NITHIN 2 836786 M 3 Y N 9 C 2 P 2 NG
RISHIKANTH 1 836784 M 3 Y N 8 C 2 P 3 NG
STEPHENRAJ 3 836785 M 4 Y Y 9 C 2 P 1 NG
KABINATHAN 2 837312 M 3 Y Y 10 C 1 P 2 NG
JEEVASRI 1 837317 F 5 Y N 11 C 2 P 3 NG
SARATH 3 837320 M 3 Y Y 15 C 2 P 2 NG
JACQUELINE 2 837370 F 3 Y Y 13 C 2 P 1 NG
IBA 1 838368 F 3 Y N 12 C 2 P 2 NG
SANTHOSH 2 838379 M 3 Y Y 8 C 2 P 2 NG
MOHAN 1 838380 M 4 N N 15 C 1 P 4 G KL R R R R R R R S S R R S S
KEERTHANA 3 838382 F 3 Y Y 11 C 2 P 2 NG
NIRANJAN 2 838383 M 3 Y N 9 C 2 P 1 NG
JEBA 1 838385 F 3 Y N 8 C 1 P 1 NG
CHITRA 1 838386 F 5 Y N 17 D 1 P 4 G ENT R R R R R R R R R R R R R
SANJANA 1 838389 F 5 Y N 14 C 1 P 3 NG
JAYAKUMAR 2 838390 M 3 Y Y 15 C 2 P 1 NG
NAREN 3 838392 M 3 Y Y 8 C 2 P 2 NG
JAGADEESH 3 838394 M 5 N N 17 C 2 P 2 G PS R R R R R R R S R R R S S
KARTHI 2 838397 M 4 Y N 11 C 2 P 2 NG
SUVETHA 3 838398 F 4 N N 12 C 1 P 3 G STAPH S S S S S S S S S S S S
VIMAL 2 838399 M 5 N N 12 C 2 P 4 G STAPH R S S S S S S S S R S S
APPU 1 838400 M 5 N N 14 C 1 P 4 G STAPH R R R R R S R R R R S S
KARTHIK 3 838411 M 3 Y Y 8 C 2 P 2 NG
SAROJA 2 838420 F 4 Y Y 9 C 2 P 1 NG
SARANYA 1 838424 F 3 N N 8 C 2 P 1 NG
LOGESH 3 838425 F 3 Y Y 9 C 2 P 2 NG
VETRIVEL 1 838427 M 5 N N 14 D 1 P 4 NG
DARUNESH 2 838429 M 4 N N 16 D 2 P 3 NG
JEYACHANDRAN 2 838430 M 4 N N 14 C 2 P 4 G KL R R R S S S S S S R R S S
VARUN 1 838440 M 5 Y N 17 C 2 P 3 G STAPH R R R S S S S S R R S S
 
